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I Introduction 1
I Introduction 
With the human genome project approaching completion (International Human Genom 
Sequencing Consortium 2004), there is a growing interest in functional analysis of gene 
products. Protein microarrays are being utilized for functional proteomic analysis, providing 
information not obtainable by DNA microarrays (Espina et al. 2004). This is not unexpected 
because DNA microarrays cannot give information about protein posttranslational 
modifications or protein-protein interactions. Protein microarrays, on the other hand, can be 
designed to monitor these molecular interactions and provide a means of differential display 
of a cell population’s proteome as well as high-throughput formats for drug discovery 
(Greenbaum et al. 2002; Ring and Ellis 2002; Wilson and Nock 2003). Within the past few 
years, researchers have begun to realize the goal of proteomic-scale analysis of protein-
protein, protein-ligand, enzyme-substrate or protein-drug interactions and thus created a new 
scientific trend (Zhu and Snyder 2003). This scientific trend and the economically requests 
within the field of proteomics and protein drug development describe the need for novel 
microarray technologies, addressing the problems of current protein microarray platforms. 
The two key problems for the construction of protein microarrays are the requirement for 
individual production of active proteins, which necessitates proteome-wide protein 
expression, and the immobilization of proteins onto surfaces, which can affect their activity 
(Lee and Mrksich 2002). Currently, specific capture molecules have to be designed for all 
possible proteins encoded by the genome. The classical capture molecules for proteins are 
antibodies, which are difficult to manufacture with known affinity and specificity. This requires 
individual validation of antibody specificity and sensitivity prior to use as a probe for protein 
microarrays (Templin et al. 2002; Liotta et al. 2003). 
Within this thesis a novel protein microarray platform based on phage display technology is 
presented. Phage display is a powerful tool for the generation and screening of protein and 
peptide libraries in order to determine specific protein-protein interactions and allow the 
identification of novel therapeutic or diagnostic proteins as well as vaccines (Smith and Scott 
1993; Smith and Petrenko 1997). Filamentous bacteriophages are capable of displaying 
foreign proteins on their surface and thus provide a universal linker for immobilization of 
these proteins on the surface of a protein microarray device. Proteins and peptides are 
functionally displayed on phage particles and by the establishment of bispecific filamentous 
bacteriophages, a side-directed immobilization of protein or peptide libraries on the surface 
of a microarray device without loss of activity becomes feasible. In addition, proteome-wide 
protein expression is possible by the generation and usage of cDNA phage libraries. The 
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development of bispecific filamentous bacteriophages and a suitable biochip platform 
represents the initial step toward the establishment of a new generation of protein 
microarrays allowing the analysis of protein-protein interactions on a single molecule level 
and in addition addressing the key problems of current protein microarrays. 
 
I.1 Filamentous bacteriophages 
Filamentous bacteriophages belong to a group of single-stranded DNA viruses encapsidating 
their circular genome in a long protein capsid cylinder. As the name implies, these 
bacteriophages are specific for F plasmid containing Escherichia coli bacteria and use the tip 
of there F pilus as a receptor. The most extensively studied filamentous bacteriophages are 
the nonlytic Ff class phages f1, fd and M13. The genome of these three phages shows 98% 
homology and consequently the protein sequence of their gene products are practically the 
same (Van Wezenbeek et al. 1980; Beck and Zink 1981; Hill and Petersen 1982). 
 
I.1.1 Structure of filamentous bacteriophages 
The Ff phage is approximately 8-10nm in diameter and 930nm in length (Fig.I-1). The phage 
genome is a single-stranded, covalently closed DNA molecule of about 6400 nucleotides and 
is protected by a somewhat flexible protein cylinder. The filamentous structure of the phage 
coat is comprised of 2600 copies of the major coat protein pVIII, each consisting of 50 amino 
acids sticking with their C-terminus to the ssDNA molecule. At one end of the particle, there 
are about five copies of the 33-residue minor coat protein pVII and five copies of the 32-
residue minor coat protein pIX. The other end contains approximately five molecules each of 
the 406-residue minor coat protein pIII and the 112-residue minor coat protein pVI. The DNA 
is orientated within the virion such that a 78-nucleotide hairpin region called the packaging 
signal (PS) is always located at the end of the particle containing the pVII and pIX proteins. 
The pVIII cylinder of the filamentous bacteriophage has been described in great detail 
(Marvin et al.1994; Overman and Thomas 1995; Williams et al. 1995; Marvin 1998). The 
pVIII monomers are present in the particle as an uninterrupted α-Helix except for their N-
terminal 5 amino acids. The pVIII monomers are packed quite tightly, as only three residues 
are accessible by proteases (Terry et al. 1997). The C-terminal 10-13 residues of pVIII form 
the inner wall of the phage coat. This region possesses four positively charged lysine 
residues that reside on one face of an amphiphilic helix. These positive charges interact with 
the sugar phosphate backbone of the DNA that is present in the particle with the bases 
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pointed inwards (Greenwood et al. 1991; Marvin et al. 1994). The N-terminal portion of pVIII 
is present on the outside of the phage. The residues connecting N- and C-terminus of pVIII 
interact with the same region of other pVIII monomers in order to form the stable but flexible 
inner core of the protein cylinder. Most of this middle portion of pVIII spans the periplasmic 
membrane of bacterial host cells before being assembled into mature progeny phage. 
 
 
           
 
 
 
       pIII    pVII 
    pVI    pIX 
    pVIII    ssDNA 
     
Fig.I-1: Structure of filamentous bacteriophage. A: Electron micrograph of a filamentous 
bacteriophage (Kay et al. 1996); B: Schematic diagram of the structure of filamentous 
bacteriophage describing its coat morphology with the five coat proteins, pIII, pVI, pVIII, 
pVII and pIX encapsidating the circular single-stranded phage DNA. 
 
The first part of the phage being assembled is the end containing the packaging signal. This 
end has approximately five copies each of the small hydrophobic pVII and pIX proteins 
(Houbiers et al. 1999; Houbiers et al. 2001A; Houbiers et al. 2001B). Currently it is not known 
how these minor coat proteins are arranged at the end of the phage and how they are 
interacting with the pVIII cylinder. Attempts to model this end of the phage suggest that one 
of these proteins must be sticking closely to the DNA, whereas the other one is exposed to 
the outside (Makowski 1992). The fact that antibodies specific for pIX but not for pVII are 
able to interact with one end of the phage indicate that only pIX is exposed and pVII is 
buried. Data obtained by immunoprecipitation experiments of detergent-disrupted phage 
100nm 
A: 
B: 
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suggest an interaction between pVII and pVIII in the intact particle and thus confirm the 
described model of this end of the phage (Endemann and Model 1995). 
The other end of the filamentous bacteriophage consists of five copies each of the minor coat 
protein pIII and pVI, accounting for about 10-16nm of the phage length (Specthrie et al. 
1992). pIII consists of the three domains pIII-D1, pIII-D2 and pIII-CT separated by glycine-
rich regions shown in Fig.I-2 (Stengle et al. 1990).  
 
Fig.I-2: Domain structure of the minor coat protein pIII. G1: glycine-rich linker region 1; 
G2: glycine-rich linker region 2; D1: domain 1 of pIII coat protein (pIII-D1); D2 domain 2 of 
pIII coat protein (pIII-D2); CT: C-terminal domain of pIII coat protein; pVI: minor coat protein 
pVI; pVIII: major coat protein pVIII. 
The first domain, pIII-D1, contains the N-terminal 68 amino acids and is responsible for the 
injection of the phage genome into the bacterial cytoplasm during the infection process. 
Amino acid residue 87-217 of pIII form the second domain, pIII-D2, which is responsible for 
binding to the bacterial F pilus (Deng et al. 1999). Both domains show specific 3D structures 
required for their function and are formed by intramolecular disulfide bonds within each 
domain (Kremser and Rasched 1994). The structure of these two domains has been 
analyzed by NMR spectroscopy and X-ray crystallography (Riechmann and Hollinger 1997; 
Lubkowski et al. 1998; Hollinger et al. 1999). pIII-D1 and pIII-D2 are exposed on the surface 
of the phage and are essential for phage infectivity. Removal of these two domains for 
example by proteolytic cleavage results in non-infectious phage (Gray et al. 1981; Armstrong 
et al. 1981). The third domain of pIII, pIII-CT, is built by the C-terminal 150 amino acid 
residues and is responsible for the stability of the phage (Crissman and Smith 1984; Kremser 
and Rasched 1994). The CT domain of pIII together with pVI interacts with the pVIII cylinder 
at the end of the assembly process before the phage is released from the bacterial 
membrane (Rakonjac et al. 1999). The interaction of pIII and pVI was also proven by 
CT
D2
D1
pVI
pVI
pVIIIpVIII
G2 
G1 
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immunoprecipitation experiments of detergent-disrupted phages (Gailus and Rasched 1994; 
Endemann and Model 1995). Very little is known about the structure and the function of the 
minor coat protein pVI. However, as pVI is not accessible to anti-pVI antisera when 
incorporated in a complete phage (Endemann and Model 1995) it is proposed that the 
hydrophobic N-terminus of pVI is buried within the particle, whereas the C-terminus is 
located near the surface (Makowski 1992). This hypothesis was confirmed by the data of 
Jespers et al. who showed that filamentous bacteriophages can be produced displaying 
foreign proteins fused to the C-terminus of pVI (Jespers et al. 1995). Minor coat protein pVI 
seems to be the only phage coat protein orientated with the C-terminus outside of the phage. 
I.1.2 Genome of filamentous bacteriophages 
The M13, f1 and fd phage genomes have been completely sequenced (Van Wezenbeek et 
al. 1980; Beck and Zink 1981; Hill and Petersen 1982). Table I-1 gives an overview of the 
size and function of the eleven genes encoded by the phage genome.  
 
Table I-1: Genes and gene products of filamentous bacteriophages. 
Gene Function No. of amino acid Protein MW (kDa) Final location 
II replication of DNA 410 46.137 cytoplasm 
X replication of DNA 111 12.672 cytoplasm 
V ssDNA binding 87 9.682 cytoplasm 
VIII major coat protein 50 5.235 virus cylinder 
III minor coat protein 406 42.522 virus tip 
VI minor coat protein 112 12.342 virus tip 
VII minor coat protein 33 3.599 virus tip 
IX minor coat protein 32 3.650 virus tip 
I assembly 348 39.502 inner membrane 
IV assembly 405 43.476 outer membrane 
XI assembly 108 12.424 inner membrane 
According to their function in the life cycle of the filamentous bacteriophages, the genes are 
grouped within the phage genome (Fig.I-3). The first group of genes (geneII, V and X) 
encodes proteins which are required for the replication of the phage genome. The second 
group (geneVII, IX, VIII, III and VI) encodes phage coat proteins and the third group (geneI, 
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XI and IV) encodes proteins which are essential for the phage assembly. Gene product pX 
and pXI are the result of a translation starting at an internal methionine codon in geneII and I, 
which is in-frame and thus resulting in smaller proteins with the same amino acid sequence 
as the C-terminus of their larger counterparts (Model and Russel 1988; Guy-Caffey et al. 
1992; Rapoza and Webster 1995). In addition, the phage genome possesses a short 
sequence called the intergenic region that does not encode for any protein. This intergenic 
region contains the origin for the synthesis of viral (+) and complementary (-) DNA as well as 
the packaging signal which is located near geneIV. 
The (-) strand of the double-stranded intermediate in viral DNA replication is required for 
transcription. Therefore, the messages produced have the same sequence as the (+) strand. 
Transcription is starting from geneII through geneIV and is directed counterclockwise. 
Transcription is stopped by two strong terminators (T), a rho-independent one just behind 
geneVIII and a rho-dependent one located in the intergenic region. These terminators divide 
the phage genome into two main transcription regions. One is a frequently transcribed region 
containing geneII through geneVIII and the other one is an infrequently transcribed region 
containing geneIII through geneIV.  
                        
Fig.I-3: Genome organisation of filamentous bacteriophage. This genomic map shows 
the relative positions of the genes, important promoters and terminators in the genome of 
filamentous bacteriophage. IR refers to the intergenic region; T, the two strong terminators; 
t, the weak terminator in geneI; GA, GB, GH, the promoters of the frequently transcribed 
regions; P, the promoters for the infrequently transcribed regions; +/- ori, the relative 
position of the origin of replication for the viral (+) and the complementary (-) DNA strand. 
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The three strong promoters, GA, GB and GH, are responsible for initiation of transcription of 
the frequently transcribed region resulting in three different transcripts all terminated 
behind geneVIII. The smallest and most stable RNA molecule is the not processed transcript 
starting from GH. The transcript starting from GA and GB are rapidly processed into five 
smaller and more stable mRNA molecules (Stump and Steege 1996). All six mRNAs are 
encoding pVIII because they utilize the same terminator at the end of geneVIII. The four 
largest of the processed mRNAs also encode pV. These two proteins, pV and pVIII, are 
needed and produced in large amounts because pVIII is the major coat protein forming the 
virion cylinder and pV interacts with the ssDNA during replication. The single stranded 
binding protein pV is required for protection of the ssDNA in the bacterial cytoplasm and for 
their transport to the periplasmic membrane. In contrast, only small amounts of pVII and pIX 
are needed and produced, even though their genes are located on the same mRNA between 
geneV and geneVIII. The translation of geneVII and geneIX is coupled to the translation of 
geneV, because the initiation site for translation of geneVII is inherently inactive and masked 
by the secondary structure of the mRNA (Ivey-Hoyle and Steege 1989; Ivey-Hoyle and 
Steege 1992; Stump and Steege 1996). Model and Russel showed that there is also 
translational regulation for the synthesis of pII and pX (Model and Russel 1988). In addition 
to the before mentioned ssDNA binding function, pV is also able to bind specifically to the 
mRNA of geneII and geneX and thus inhibiting their translation. Binding only occurs at high 
concentrations of pV, when there is more pV than needed for binding to newly synthesized 
viral ssDNA.  
The transcription initiation of the infrequently transcribed region is regulated by two major 
promoters (P) located before geneIII and geneIV, respectively. Transcription starting from the 
promoter upstream of geneIII gives two classes of mRNA because there is a weak rho-
dependent terminator (t) in the beginning of geneI. The most abundant class encodes only 
geneIII and VI, whereas there is less mRNA encoding geneIII, VI and I/XI. The resulting 
down-regulation of pI is important, as pI is able to form channels in the bacterial membrane 
and lethal in high concentration. Substantial amounts of pIV mRNA are produced from the 
promoter located at the end of geneI and XI.  
There are only two regions within the phage genome that do not encode for proteins, the 
intergenic region and the small region between the end of geneVIII and the beginning of 
geneIII. Currently, only these two regions and the position between geneIII leader and 
geneIII are used for modifications of the phage genome, for example the insertion of an 
antibiotic resistance in the intergenic region (Zacher et al. 1980) or the insertion of a cloning 
site into geneIII (McCafferty et al. 1990; Clackson et al. 1991). For insertion of DNA 
sequences between geneVIII and geneIII, the positions of the terminator and the promoter in 
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this region must be altered to maintain their function. In addition, care has to be taken not to 
interfere with the origins of replication or other control areas. Similarly, it is not recommended 
to disturb normal terminators or promoters. There appears to be a delicate balance in the 
synthesis of phage proteins that allow phage production without seriously affecting bacterial 
growth (Model and Russel 1988, Webster 1996). These observations and the fact that the 
transcription and translation of the phage genome is highly regulated by multiple control 
elements on a relatively small DNA molecule indicate that successful genetic modifications of 
the phage genome are difficult to achieve. 
 
I.1.3 Life cycle of filamentous bacteriophages 
I.1.3.1 Infection process of filamentous bacteriophages 
Phage infection is a multistep process requiring interactions between the phage coat protein 
pIII and the bacterial F pilus as well as the cytoplasmic membrane proteins TolQ, R and A as 
shown in Fig.I-4. The bacterial F pilus is assembled and extended from pilin subunits in the 
cytoplasmic membrane of the bacterial cell. The proteins which are responsible for the 
structure, assembly and disassembly of the pilus are encoded by genes in the tra operon 
located on the F plasmid (Frost et al. 1994). The normal function of the F pilus is the conjugal 
transfer of DNA from a bacterial donor cell into a recipient cell (Firth et al. 1996). This DNA 
transfer, called conjugation, is initiated by the interaction of the tip of the F pilus with the 
envelope of the recipient bacterium. Then the F pilus retracts and draws the donor and 
recipient together to facilitate the DNA transfer.  
This mechanism is used by filamentous bacteriophage in order to infect bacteria and inject 
their genome into the host cell. The infection is initiated by the binding of pIII-D2 domain 
(Fig.I-2) of the phage coat protein pIII to the tip of the bacterial F pilus (Stengle et al. 1990; 
Deng et al. 1999). The exact binding site of pIII-D2 is unknown. Probably, it is not the same 
one recognized by pIII-D1, because purified pIII fragments pIII-D2 and pIII-D1-D2 appear to 
compete equally well with wild type phages for binding to the F pilus (Krebber et al. 1997; 
Deng et al. 1999). After the phage binds to the bacterium, the F pilus starts retracting and 
draws the pIII end of the phage to the periplasm. It is not known whether the retraction of the 
pilus is the result of a normal assembly-retraction cycle or whether the phage attachment is 
triggering the retraction process (Firth et al. 1996).  
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Fig.I-4: Infection process of filamentous bacteriophage. The membrane topology of the 
Tol proteins is shown. TolD1, tolD2 and tolD3 refer to the three domains of TolA. D1: 
domain 1 of pIII coat protein of the filamentous bacteriophage (pIII-D1); D2 domain 2 of pIII 
coat protein of the filamentous bacteriophage (pIII-D2); tolD1: domain 1 of bacterial TolA 
protein; tolD2: domain 2 of bacterial TolA protein; tolD3: domain 3 of bacterial TolA protein; 
OM: outer membrane; CM: cytoplasmic membrane. 
After retraction of the F pilus, interaction between domain pIII-D1 of phage coat protein pIII 
and the bacterial Tol proteins is necessary for injection of the phage genome into the 
bacterial cytoplasm (Riechmann and Hollinger 1997). TolQ, R and A are bacterial proteins 
that appear to be required for maintaining the integrity of the bacterial outer membrane 
(Lazzaroni et al. 1999). Mutations in gene tolQ, R and A lead to hypersensitive bacteria that 
do not tolerate various detergents and drugs. In addition, these bacteria release periplasmic 
proteins into the medium and form outer membrane vesicles (Webster 1991; Bernadac et al. 
1998). All three of these Tol proteins are located in the cytoplasmic membrane of the 
bacterial cell and appear to form a complex via interactions among their transmembrane 
domains (Lazzaroni et al. 1995; Germon et al. 1998). TolQ spans the cytoplasmic membrane 
three times, with most of its residues located in the cytoplasm (Kampfenkel and Braun 1993; 
Vianney et al. 1994). TolA and R just possesses one transmembrane domain located near 
their N-terminus and the bulk of their residues are exposed in the periplasmic space 
(Levengood et al. 1991; Muller et al. 1993). TolA consists of three domains, which are 
separated by glycine-rich regions. Domain 1 (tolD1) comprises the N-terminal 43 amino acid 
residues, which anchor the protein to the cytoplasmic membrane. Domain 3 (tolD3) is formed 
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by the C-terminal portion of approximately 108 residues that appear to interact with the outer 
membrane (Levengood-Freyermuth et al. 1993). TolD1 and tolD3 are connected by the 
central domain (tolD2), which contains a α-helical structure long enough to span the 
periplasmic space. 
These three Tol proteins, TolQ, R and A, are required during phage infection for translocation 
of the phage genome into the cytoplasm and translocation of the phage coat proteins into the 
cytoplasmic membrane (Russel et al. 1988; Click and Webster 1998). Binding of domain pIII-
D2 of the phage coat protein pIII to the bacterial pilus releases pIII-D1 from pIII-D2 and 
allows pIII-D1 to interact with domain 3 of TolA (tolD3) after retraction of the pilus 
(Riechmann and Hollinger 1997). The tip of the F pilus is the receptor for phage attachment 
and tolD3 acts as the coreceptor. Structural analysis shows that both pIII-D2 and tolD3 are 
binding to the same region of pIII-D1, even though there is no topological similarity between 
pIII-D2 and tolD3 (Lubkowski et al. 1999). Therefore, the binding of the pilus tip to pIII-D2 
must displace the pIII-D1, making it available for interacting with tolD3. Recently, it has been 
shown that binding of pIII-D1 to tolD3 is necessary for the initiation of translocation of the 
phage genome into the bacterial cytoplasm but the subsequent steps involved in phage 
infection remain unknown.  
I.1.3.2 Replication and translation of the phage genome 
After phage infection and translocation of the viral (+) strand DNA into the cytoplasm of the 
host cell, the complementary (-) strand is synthesized by the bacterial enzyme machinery. 
The resulting dsDNA is modified by gyrase, a type II topoisomerase that catalyzes the 
formation of negative supercoiled DNA. The final product is a covalently closed, supercoiled, 
dsDNA called the replicative form (RF). The (-) strand of the RF is the template for 
transcription and the resulting mRNAs are translated into all of the phage proteins. One of 
these phage proteins, pII, nicks the (+) strand of the RF at a specific position in the intergenic 
region. The nick allows the synthesis of a new viral strand by replication via “rolling circle”. 
After one round, pII circularizes the new viral (+) strand DNA, which is then converted again 
to a covalently closed, supercoiled, dsRF molecule. By this, a pool of RF molecules is 
produced that can direct the synthesis of the phage proteins. RF molecules are synthesized 
until the amount of phage protein pV reaches a critical concentration. As described above 
(I.1.1), pV is able to cooperatively bind newly synthesized viral ssDNA after forming dimers 
and thus prevents its conversion to additional RF molecules. Therefore, the presence of 
adequate amounts of pV switches most of the DNA replication to the synthesis of ss(+) viral 
DNA. pV is protecting the viral ssDNA by forming a pV-DNA structure about 800nm long and 
8nm in diameter (Gray 1989; Skinner et al. 1994; Guan et al. 1995; Olah et al. 1995). The 
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packaging signal (PS) is exposed on one end of the pV/DNA complex and is not decorated 
with any pV protein (Bauer and Smith 1988). The pV/DNA particle is the substrate for the 
phage assembly, which is initiated at the end exposing the PS. The exact role of pX in the 
replication process is unclear, but it appears to function as an inhibitor of pII and thus is 
involved in the regulation of the amount of viral DNA produced (Fulford and Model 1984). 
 
Fig.I-5: Life cycle of filamentous bacteriophages. Infection: sequential binding of phage 
pIII coat protein to the tip of the host F pilus followed by retraction of the pilus. Binding of 
phage pIII coat protein to the host TolA protein and injection of the ssDNA phage genome 
into the bacterial cytoplasm. Replication: ssDNA is converted by host enzymes to the 
double-stranded RF, which serves as template for gene expression. Assembly: coat 
proteins pVII, pIX, pVIII, pIII and pVI are directed to the periplasmic membrane. Substrate 
for the assembly process is the pV-ssDNA complex. pV dimers are replaced by pVIII as the 
ssDNA is extruded through the bacterial membrane using the pI/pXI/pIV-channel. RF: 
replicative form; PS: packaging signal. 
The only phage proteins remaining in the bacterial cytoplasm are pII, pX and pV, which are 
the three proteins being engaged in the replication process. All other phage proteins are 
synthesized and inserted into the cytoplasmic or outer membrane. The phage coat proteins, 
pVIII, pIII, pVI, pVII and pIX have been shown to reside in the cytoplasmic membrane 
(Endemann and Model 1995; Williams et al. 1996; Papavoine et al. 1997). The major coat 
protein pVIII and minor coat protein pIII are synthesized each with N-terminal signal-
peptides, which are removed after membrane insertion. The remaining three minor coat 
protein, pVI, pVII and pIX are synthesized without signal peptides and their mechanism for 
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insertion into the bacterial membrane is unknown. It has been shown that pVIII and pIII are 
inserted into the cytoplasmic membrane with their N-terminus toward the periplasmic space 
(Davis et al. 1985; McDonnell et al. 1993) whereas the orientation of pVII and pIX is thought 
to be the same as the one of pVIII and pIII. Currently no convincing data regarding the 
topology of pVI in the cytoplasmic membrane of the bacterial cells are available. 
The three assembly proteins, pIV, pI and pXI, are also integral membrane proteins. pIV is 
synthesized with an N-terminal signal peptide and is translocated into the periplasm, 
probably using the Sec system of the host bacterium (Raposa and Webster 1993; Russell 
and Kazmierczac 1993). Twelve to fourteen pIV molecules are forming channels across the 
outer membrane with a diameter of 6-8nm, which is large enough to accommodate an 
extruding phage (Kazmierczak et al. 1994; Linderoth et al. 1997). This channel must be 
gated in some way, as it does not let large molecules in or out of the periplasm in absence of 
other phage proteins (Marciano et al. 1999). The other two assembly proteins, pI and pXI, 
are synthesized without any signal peptide and are inserted into the cytoplasmic membrane 
in a manner that requires SecA (Rapoza and Webster 1993). It is assumed that pI and pXI 
interact with each other in order to create channels in the cytoplasmic membrane, which 
could then interact with the outer membrane pVI complex to form a channel through both 
bacterial membranes during phage assembly (Guy-Caffey and Webster 1993; Rapoza and 
Webster 1995). 
I.1.3.3 Assembly process of filamentous bacteriophages 
The assembly process of filamentous bacteriophages is a membrane-associated event, 
which does not cause lysis of the host cell. The assembly requires the five phage coat 
proteins, the three assembly proteins, ATP, a proton motive force and at least one bacterial 
protein, which is thioredoxin (Model and Russel 1988; Feng et al. 1997). The initiator for the 
assembly process is the pV/DNA complex. In principle the assembly is a process in which 
the pV dimers are removed and the coat proteins are assembled around the viral ssDNA as it 
is extruded through the bacterial membranes. The assembly process can be divided into 
initiation, elongation and termination. The process is initiated by interaction of the PS, which 
is exposed in the pV/DNA complex and the C-terminal portion of pI and the membrane-
associated proteins pVII and pIX together with the first set of pVIII molecules (Lopez and 
Webster 1983; Russel and Model 1989). The order in which pVII, pIX and pVIII associate 
with the PS is unknown. One hypothesis is that pI is able to direct an ordered assembly of 
these three coat proteins around the PS to form the phage tip. Perhaps, this assembly 
induces a conformational change in pI, allowing its periplasmic region to interact with pIV and 
open the gate of the pIV channel (Russel et al. 1997; Marciano et al. 1999). After initiation, 
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the phage has to be elongated by removing pV dimers and replacing them with pVIII as the 
DNA is extruded through the bacterial membranes. The structure of the DNA in the pV/DNA 
complex is different from its structure in the assembled phage, suggesting that some 
conformational change in the DNA is required to allow the interaction with pVIII. Rapoza and 
Webster showed that the ten residues of pI and pXI adjacent to the cytoplasmic face of the 
cytoplasmic membrane have an amphiphilic character extremely similar to the C-terminal 
residues of pVIII that interact with the viral ssDNA (Rapoza and Webster 1995). These 
regions of pI and pXI may interact with the viral DNA that has just been stripped of the pV 
dimers, to facilitate the adoption of the DNAs’ conformation for interaction with pVIII. In 
addition the conformation of pVIII has to change before being assembled with the viral DNA. 
The structure of this protein is somewhat different in the assembled phage than in the 
bacterial membrane, where it tends to form dimers that are not suitable for packaging (Haigh 
and Webster 1998; Marvin 1998). When the end of the viral DNA is reached, assembly is 
terminated by the incorporation of pVI and pIII. In the absence of pIII, elongation continues 
with pVIII encapsulating another phage DNA. This process is resulting in the production of so 
called polyphage, which are not released from the bacterial membrane (Model and Russel 
1988; Rakonjac and Model 1998). The exact mechanism by which pVI and pIII are added to 
the end of the bacteriophages and how the assembly process is terminated is unknown.  
 
I.2 Phage display 
The generation of new drugs has long involved the screening of hundreds of thousands of 
compounds with well defined in vitro assays, seeking leads to mimic as closely as possible 
the desired in vivo activity of the new drug. New library methodologies offer many alternative 
routes that are at least as powerful as traditional approaches such as combining the 
generation of billions of compounds with a fast screening or selection procedure to identify 
interesting lead candidates. One of the most powerful tools and the most widely used library 
methodology is the so called phage display technology (Smith 1985). This technology is 
based on the use of filamentous bacteriophage for screening of libraries containing millions 
or even billions of different peptides or proteins. The most successful application of phage 
display has been the isolation of recombinant antibody fragments using large phage antibody 
libraries (Winter et al. 1994; Hoogenboom and Chames 2000). The principle of the phage 
display technology is shown in Fig.I-6: 
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Fig.I-6: Principle of phage display technology using a phagemid vector. Genes 
encoding for millions of variants of ligands or binding molecules are cloned into a phagemid 
vector carrying the gene encoding for one of the five phage coat proteins (pIII is shown 
here). Large phage libraries can be obtained by transforming E. coli with the phagemids 
and rescue of the phages with a helperphage. From these repertoires, phages displaying 
the specific-binding ligand can be isolated by a series of recursive cycles of selection on 
the target, each of which involves binding, washing, elution and amplification. 
DNA encoding for millions of variants of certain ligands/binding molecules (e.g., peptides, 
proteins or protein fragments) is cloned into the phage genome as a fusion to one of the 
genes encoding the five phage coat proteins (pIII, pVI, pVII, pVIII or pIX). Upon expression, 
the chimeric coat protein fusion will be packaged into new progeny phages that are 
assembled in the bacterial host. Expression of the fusion product and its subsequent 
incorporation into the mature phage coat results in the ligand being displayed on the phage 
surface, whereas its genetic information resides within the phage. This connection between 
ligand genotype and phenotype allows the enrichment of specific binding phages, e.g., using 
selection on an immobilized target. Phages that display a relevant ligand will be retained, but 
nonadherent phages will be washed away. The specific binding phages can be recovered 
from the surface, used for re-infection of host bacteria and amplified again. The resulting 
phages are subjected to another round of affinity purification and multiple rounds of this 
procedure lead to an enrichment of phages containing specific binding ligands. This type of 
enrichment, using several rounds of binding between the displayed ligand and its 
immobilized target, is sometimes referred to as “panning” (Parmley and Smith 1988). Many 
variations of this procedure have been devised to reduce the enrichment of non-specific 
binding phages and to increase the specificity and kinetics of binding to desired targets. 
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Large libraries of peptides and proteins have been created using pIII as the display vehicle 
(Smith and Scott 1993; Winter et al. 1994), leading to the development of a number of 
techniques for selecting the molecules desired from such libraries (Clackson and Wells 1994; 
Hoogenboom 1997). Peptides and proteins have also been fused to the N-terminus of the 
major coat protein pVIII (Iannolo et al. 1995; Malik et al. 1996). In addition, there has been a 
report of phages displaying proteins fused to the C-terminus of pVI (Jespers et al. 1995). 
This allows the construction of full-length cDNA libraries because the stop codon of the 
cDNAs is not effecting the expression of the cDNA/pVI fusion proteins when cloned to the 3’-
end of geneVI, although the efficiency of display appears to be lower. In addition, antibody 
heavy- and light-chain variable regions as well as peptides have been fused to the N-
terminus of pVII and pIX and displayed on filamentous phages, showing that these two minor 
coat proteins can also be used for phage display (Gao et al. 1999; Gao et al. 2002a; Gao et 
al. 2002b; Gao et al. 2003). However, the majority of proteins or peptides displayed on 
filamentous bacteriophages are fused to either pIII or pVIII and selected by panning on solid 
phase, in solution or even on cells. 
The first antibodies were successfully displayed on the surface of filamentous 
bacteriophages by McCafferty (McCafferty et al. 1990). This was achieved by fusing the 
coding sequence of the antibody variable (V) regions encoding a single chain Fv (scFv) to 
the N-terminus of the minor coat protein pIII using a phage vector based on the genome of 
fd-tet phage (Zacher et al. 1980). The scFv sequence was cloned in frame with geneIII and 
downstream of the geneIII signal sequence, which directs the fusion protein to the 
periplasmic space. In the periplasmic environment, the VH and VL domains fold correctly and 
form a functional scFv (Skerra et al. 1988; Better et al. 1988). Initially, phage vectors that 
carried all the genetic information required for the phage life cycle were used (Zacher et al. 
1980; Skerra et al. 1988; Better et al. 1988; Clackson et al. 1991; McCafferty et al. 1990), but 
phagemid vectors have since become the most popular vector system for phage display. 
Phagemids are small plasmid vectors that have high transformation efficiencies and are 
therefore ideally suited for the generation of large peptide or protein libraries (Bass et al. 
1990; Breitling et al. 1991; Barbas et al. 1991; Hoogenboom et al. 1991; Marks et al. 1991). 
These phagemid vectors contain the filamentous phage intergenic region with the origin of 
replication for viral and complementary strand synthesis as well as the hairpin packaging 
signal. In addition, they contain a plasmid origin of replication and a gene encoding 
resistance to specific antibiotic. Phagemids also carry geneIII, geneVI, geneVII, geneVIII or 
geneIX with appropriate cloning sites for the construction of the peptide or protein libraries. 
The gene expression is under control of a specific inducible promoter. The phagemid can 
maintain itself as a plasmid, directing expression of the protein in bacteria if desired. Infection 
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of phagemid carrying bacteria with a filamentous helperphage activates the phage origin of 
replication, resulting in single-stranded phagemid DNA being encapsulated into recombinant 
phages using the helperphage encoding proteins. The commonly used helperphage contains 
a defective packaging signal so that the majority of produced phages contain the single-
stranded phagemid DNA, which is necessary for connecting genotype and phenotype of the 
library proteins (Russel et al. 1986). Since the helperphage genome encodes the wild type 
coat proteins, typically over 90% of rescued phages do not display the library protein at all. In 
addition, the vast majority of the recombinant phages that do display the fusion product will 
only contain a single copy of the library protein, comparing to multivalent display of foreign 
proteins when using a phage vector (Marks et al. 1992; O’Connell et al. 2002). Ideally, phage 
vectors leading to multivalent display would therefore be preferable when selecting large 
antibody libraries to guarantee selection with a limited number of phages. Monovalent 
display by using phagemid vectors, on the other hand, may be essential when selecting 
antibodies of higher affinity (O’Connell et al. 2002). Therefore, the use of inducible promoters 
(Lutz and Bujard 1997) or the use of helperphages with deleted or truncated geneIII (Duenas 
and Borrebaeck 1995; Rondot et al. 2001), which may be efficiently produced in bacterial 
cells containing geneIII under control of the phage promoter (Rakonjac et al. 1997), may in 
future allow successful modulation of the valency of displayed library proteins. So far, these 
modified helperphages were only constructed for the pIII-display system. 
 
Fig.I-7: Phage library versus phagemid library. A: Use of phage vectors leading to 
multivalent display of the library proteins on the phage surface. B: Use of phagemid vectors 
leading to monovalent display of the library proteins on the phage surface. 
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I.3 Research objectives 
I.3.1 Protein Nanochip 
This doctoral thesis was part of an interdisciplinary Fraunhofer MAVO project entitled 
“Surface technology and photonic in proteomics”. MAVO (Markt-orientierte Strategische 
Vorlaufforschung) relates to “market oriented and precompetitive strategic research” and is 
based on internal Fraunhofer research projects. Seven Fraunhofer Institutes were involved in 
this project forming an interdisciplinary consortium called “Fraunhofer Allianz Proteinchip”. 
The main objective of this MAVO project is the development of a novel protein microarray 
enabling automation of phage display technology.  
 
Fig. I-8 Members of the “Fraunhofer Allianz Proteinchip”. 
 
Phage display (I.2) is a powerful tool for screening large protein or peptide libraries in order 
to identify novel therapeutics, diagnostics or vaccines. The emerging arena of protein based 
drug development urgently requires high-throughput technologies for automated library 
handling and phage display selection. Currently, technologies have been developed by 
adapting the basic selection steps of the panning procedure to robotic platforms (Walter et al. 
2001; Konthur and Walter 2002; Hallborn and Carlsson 2002; Bradbury 2003b). The 
Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Fraunhofer 
Institute for Laser Technology ILT (Aachen; Germany) developed an innovative strategy for 
the generation of a novel high-throughput screening system, called Protein Nanochip. This 
Protein Nanochip circumvents the entire panning procedure (I.2; Fig.I-6) by direct laser-
based detection of individual binding partners, combined with fluorescent activated cell 
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sorting (FACS), and final identification of the interacting partners by Duplex-PCR and 
sequencing. This technology should be suitable for screening an immobilized phage library 
against a second phage library in solution to enable the identification of new targets and their 
specific ligands within one single screening procedure.  
 
Fig.I-9: Principle of the Protein Nanochip. The first phage library is immobilized on the 
surface of the chip via a photosensitive linker and a second fluorescently labelled phage 
library is then applied in a fluidic system to the immobilized one. After suitable washing 
steps, the exact positions of all specific binding partners on the surface of the Protein 
Nanochip are determined by two detection lasers using the fluorescent dye of the bound 
phages from the second library. Knowing the x/y-coordinates of all specific binding 
partners, a delamination laser selectively cleaves their photosensitive linker and the phage 
pairs are released from the chip and sorted by FACS for subsequent analysis. 
The principle of the Protein Nanochip is shown in Fig.I-9. The first phage library displaying 
e.g. a cDNA library is immobilized on the chip surface via a photosensitive linker, necessary 
for selective delamination of specific binding partners. The second fluorescent labelled phage 
library displaying e.g. a scFv antibody library is then added in a fluidic system to the 
immobilized library. Upon selective protein-protein interaction of the scFv-displaying phages 
with the cDNA-displaying phages the exact position of specific binding partners is detectable 
through a novel highly sensitive detection system (Currently under development at the 
Fraunhofer ILT). Detection was based on the usage of two lasers, detecting the fluorescent 
label of the captured phages from the second library.  One laser scans the chip in the x-
section and the other one in the y-section to determine the x/y-coordinate and thus the exact 
localization of the binding partners on the Protein Nanochip surface. The coordinates of the 
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x/y position of the binding partners should allow a delamination laser to selectively cleave a 
photosensitive linker thus releasing the specific phage pair. Released binding partners then 
might be separated via FACS using the fluorescent signal and analyzed by duplex PCR and 
DNA sequencing. 
The approach developed and presented within this doctoral thesis provided the initial and 
most critical step towards the realization of the Protein Nanochip. For the development of this 
new screening devise bispecific filamentous bacteriophages were to be generated, 
displaying two functional moieties on opposite sites of the particle. One side should display a 
moiety for the side-directed immobilization onto the chip surface or for fluorescent labelling 
and on the other side a peptide or protein library should be displayed for interaction with 
specific binding partners in solution. 
 
I.3.2 Aim of this thesis 
As described in I.3.1 the aim of this doctoral thesis was to use phage display technology in 
order to generate the biological entities of the Protein Nanochip (Fig.I-9). Therefore two main 
objectives needed to be achieved: 
• Generation of bispecific filamentous bacteriophages allowing simultaneous 
display of a protein or peptide library and specific moieties for immobilization or 
labelling on the opposite site of the particle. 
• Establishment of a novel technology for the side-directed immobilization of 
filamentous bacteriophages onto the surface of the Protein Nanochip. 
 
I.3.2.1 Generation of bispecific filamentous bacteriophages 
To fulfill the first aim a vector system suitable for the generation of bispecific filamentous 
bacteriophages was developed. The bispecific phages should display the protein libraries 
either as a fusion to the pIII or pVI coat protein and in parallel display functional peptides or 
proteins for the immobilization or labelling as a fusion to the pIX coat protein on the opposite 
site. The pIII-display system was chosen, because currently it is the best described phage 
display system and suitable for the screening of nearly all kinds of protein libraries (Smith 
and Petrenko 1997). However, display of full-length cDNA libraries fused to the N-terminus of 
pIII is not possible, because the stop codons of the full-length cDNAs will effect the 
expression of the related cDNA/pIII-fusion protein. Therefore, the pVI-display system was 
chosen in order to create bispecific phages allowing the screening of cDNA libraries (Jespers 
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et al. 1995). At the other end of the phage, the phage coat protein pIX was the display 
system of choice, because it had been shown that pIX-display is the more suitable screening 
system compared to pVII (Gao et al. 2003; Endemann and Model 1995). 
Two different strategies were developed to generate bispecific bacteriophages.  
I.3.2.1.1 Generation of a bispecific phage vector 
A bispecific phage vector was designed based on a derivative of the fd-tet phage vector 
(Zacher et al. 1980). Currently, only phage vectors are available allowing the display of 
foreign proteins as a pIII-fusion by cloning the corresponding gene between the geneIII 
signal sequence and geneIII (Skerra et al. 1988; Better et al. 1988). Therefore, the 
challenging task was to modify the fd-tet phage vector by inserting: 
•  a cloning site and an appropriate linker in frame with geneIII downstream of the 
geneIII signal sequence or alternatively downstream of geneVI depending on the kind 
of library that had to be screened; 
•  a cloning site and an appropriate linker in frame upstream of geneIX. 
The resulting bispecific phage vectors should allow the generation of bispecific phages 
displaying two different moieties in multivalent fashion on their opposite sites without the 
need of a helperphage. 
I.3.2.1.2 Generation of a bispecific phagemid vector 
The second strategy for the generation of bispecific phages describes the construction of a 
bispecific phagemid vector was based on the well-established pHEN phagemid 
(Hoogenboom et al. 1991). The insertion of a second cloning cassette containing geneIX 
should allow the construction of this bispecific phagemid vector. However, for generation of 
the bispecific phages an infection of the transformed bacteria with a helperphage is 
necessary. This system has the disadvantage, that only a small percentage of the produced 
phages will be bispecific and that these phages display only one copy of the two foreign 
proteins on their surface and thus are monovalent (O’Connell et al. 2002).  
As proof of principle for the two vector systems a scFv antibody gene needed to be cloned 
into the geneIII cloning site and a cDNA gene into the pVI cloning site. The functional display 
of these proteins on the surface of the resulting phages was to be confirmed by 
immunological analysis such as phage ELISA. The second specificity of the bispecific vector 
systems was to be determined by integration of a scFv antibody gene or a suitable peptide 
into the pIX cloning site. In addition, the bispecificity of the phages was to be proven using 
phage ELISA and immunogold labelling followed by subsequent electron microscopy based 
analysis.  
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I.3.2.2 Immobilization of filamentous bacteriophages 
The second aim of this thesis was the establishment of a suitable technology for the side-
directed immobilization of bispecific filamentous bacteriophages onto the surface of the 
Protein Nanochip. The prerequisite was the immobilization of filamentous bacteriophages on 
biotinylated surfaces. Therefore phages were to be generated, displaying functional 
streptavidin, avidin or other biotin binding motives as a pIX fusion. In order to reach this aim, 
a phagemid test system was to be developed allowing the display of foreign proteins or 
peptides on pIX coat protein. For the generation of this vector system geneIII was to be 
replaced by geneIX using a modified pHEN phagemid vector (Hoogenboom et al. 1991). The 
resulting pIX phagemid vector was to be used for the screening of a suitable protein or 
peptide motif, which is able to bind biotinylated surfaces when displayed on phage pIX. The 
most suitable binding motif was to be determined by phage ELISA and subsequent 
immobilization assays using the Protein Nanochip, which were to be provided by the other 
project partners. 
Finally the best binding motif needed to be integrated into the bispecific filamentous 
bacteriophages and side-directed immobilization on the Protein Nanochip needed to be 
demonstrated. 
The different tasks, necessary to reach the main objectives of this doctoral thesis are shown 
in Fig.I-10. All developed phage and phagemid vectors are listed in V.2.1 and V.2.2. 
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Fig.I-10: Flow chart of this doctoral thesis. 
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II Materials and Methods  
II.1 Materials 
II.1.1 Chemicals and consumables  
All chemicals were purchased from the following companies: Becton Dickinson Bioscience 
Clontech (Heidelberg), Biochrom (Berlin), BioRad (München), ICN (Eschwege), Gibco BRL 
(Eggstein), IBA GmbH (Göttingen), Invitrogen (Karlsruhe), New England Biolabs 
(Schwalbach), Promega (Mannheim), Roche Diagnostics (Mannheim), Roth (Karlsruhe), 
Serva (Heidelberg), VWR (Darmstadt) and Sigma (Deisenhofen). 
 
Consumables were purchased from the following companies: Amersham Pharmacia 
(Freiburg), Biozym (Oldendorf), Corning Inc. (Schiphol-Rijk, Niederlande), Eppendorf 
(Hamburg), Greiner (Solingen), Hewlett-Packard (München), IBA GmbH (Göttingen), 
Invitrogen (Karlsruhe), Kodak (Stuttgart), Millipore (Eschborn), Nunc (Biebrich), Qiagen 
(Hilden), Roth (Karlsruhe), Schott Glaswerke GmbH (Mainz), Starlab (Ahrensburg) and 
Whatman (Maidstone, England).  
 
II.1.2 Enzymes and reaction kits 
DNA was digested with restriction enzymes obtained from New England Biolabs. ExpandTM 
high fidelity Taq DNA polymerase from Roche Diagnostics was used for SOE-PCR 
(II.2.1.2.2). Taq DNA polymerase from Invitrogen was used for standard (II.2.1.2.1) and 
colony (II.2.1.2.3) PCR.  
The following kits were used: 
Kits Company 
QIAprep® Plasmid Isolation Kits (Mini, Maxi) Qiagen  
QIAquick® Gel Extraction Kit Qiagen  
QIAquick® PCR Purification Kit Qiagen  
SuperScriptTM First-Strand Synthesis Kit Invitrogen 
Quick LigationTM Kit New England Biolabs 
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II.1.3 Primary and secondary antibodies 
The following antibodies were used for detection and analysis of recombinant filamentous 
bacteriophages by ELISA (II.2.2.5) or immunogold assay (II.2.2.6): 
 
Table II-1: Primary and secondary antibodies used throughout this work. 
Antibody Epitope specificity Properties 
mouse anti-penta-His, (Qiagen) 
N-terminal, C-terminal and 
internal 6xHis tags 
monoclonal, unconjugated 
rabbit anti-6xHis, (Acris 
Antibodies, Hiddenhausen) 
N-terminal, C-terminal and 
internal 6xHis tags 
polyclonal, unconjugated 
Strep-tag® II specific mouse 
antibody, (IBA GmbH) 
N-terminal, C-terminal and 
internal Strep-tag® II 
monoclonal, unconjugated 
mouse anti-pIII (MoBiTec, 
Göttingen) 
bacteriophage M13 minor coat 
protein pIII 
monoclonal, unconjugated 
HRP-conjugated Fc specific goat 
anti-mouse IgG (GAMHRP), 
(Sigma) 
Fc of mouse IgG 
polyclonal, HRP (horseradish 
peroxidase) conjugated 
HRP-conjugated mouse anti-M13, 
(Amersham Pharmacia) 
bacteriophage M13 major coat 
protein pVIII 
monoclonal, HRP-conjugated 
15nm gold-conjugated H&L 
specific goat anti-mouse IgG 
(Biocell, Cardiff, England) 
Heavy and light chain (H&L) of 
mouse IgG 
polyclonal, gold-conjugated 
(15nm particle) 
10nm gold-conjugated H&L 
specific goat anti-rabbit IgG 
(Biocell, Cardiff, England) 
Heavy and light chain (H&L) of 
rabbit IgG 
polyclonal, gold-conjugated 
(10nm particle) 
10nm gold-conjugated goat anti-
HRP (Plano, Wetzlar)  
horseradish peroxidase 
polyclonal, gold-conjugated 
(10nm particle) 
 
All ELISA assays (II.2.2.5) were detected with secondary HRP-conjugated antibodies and 
developed with ABTS substrate (Roche Diagnostics). Color development was measured at 
405 nm against ABTS solution as a blank by photometric analysis. 
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II.1.4 Vectors 
II.1.4.1 Phage vectors 
II.1.4.1.1 fd-tet  
Fd-tet was the first phage vector being developed by Zacher et al. (1980) and was used as a 
basic vector for generating novel phage vectors within this thesis. Fd-tet is a derivative of the 
filamentous bacteriophage fd genome and differs by the insertion of a tetracycline resistance 
cartridge into the origin of “-“strand replication, which has the effect of “de-tuning” the phage 
and making it far more tolerant of loss-of-function mutations (Parmley et al. 1988). Therefore 
fd-tet tolerates for example frame shifts and deletion of geneIII whereas the same lesion 
causes death in the parental fd infected host.  
 
II.1.4.1.2 fd-tet-DOG1 
Fd-tet-DOG1 (McCafferty et al. 1990) is a derivative of fd-tet (Zacher et al. 1980) and was 
used as another basic vector for the generation of novel phage vector. Fd-tet-DOG1 was 
designed to allow the insertion of single chain antibody cDNA sequences as fusions to the N-
terminus of geneIII product. Therefore an ApaLI-NotI-cloning site was inserted between 
geneIII leader and geneIII. These two enzymes were chosen because they are cutting rarely 
in antibody heavy and light chain variable antibody domains.  
 
II.1.4.2 Phagemid vectors 
II.1.4.2.1 pHEN4II 
pHEN4II phagemid (Zhang et al. 2001) is a derivative of the pHEN1 phagemid (Hoogenboom 
et al. 1991) and was used as a basic vector for generation of novel phagemids within this 
thesis. pHEN4II contains SfiI/BstEII- and AscI/NotI-cloning sites for cloning of heavy and light 
chain variable domains of antibodies spaced by a modified 218 poly-linker based on the 218-
Whitlow linker (Whitlow et al. 1993), which allows the easy construction of single chain 
antibody fragments. 
II.1.4.2.2 pHENHi 
pHENHi phagemid (Peschen et al. 2004) is a derivative of the pHEN4II phagemid (Zhang et 
al. 2001) and was also used as a basic vector for generation of novel phagemids. The 
pHENHi phagemid possesses an additional C-terminal 6xHis tag inserted between the C-
terminal myc-tag and the amber stop codon of pHEN4II. 
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II.1.5 Biological material 
II.1.5.1 Bacterial strains 
All intermediate gene constructs generated within this thesis are based on a phage vector 
and were transformed into E. coli XL1-Blue MR. All intermediate constructs based on a 
phagemid vector were transformed into E. coli DH5α. For phage assembly all final phage 
vectors as well as phagemid vectors were transformed into E. coli TG1. 
Table II-2: Names and genotypes of bacterial strains used throughout this thesis. 
Strain Source Genotype 
DH5α Ausubel et al.1994 F- endA hsdR17 supE44 thi-1 recA1 gyrA96 relA1 
 ∆(lacZYA-argF) Φ80d lacZ∆M15 
XL1-Blue MR Stratagene  F- ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
 supE44 thi-1 recA1 gyrA96 relA1 lac 
TG1 Stratagene supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM)5 (rK- mK-)  
[F’ traD36 proAB lacIqZ∆M15] 
 
II.1.5.2 Helperphage 
II.1.5.2.1 M13KO7 
M13KO7 helperphage is an M13 derivative, which carries the mutation Met40Ile in geneII. 
The p15A origin of replication and the kanamycin resistance gene from Tn903 were inserted 
within the M13 origin of replication (Vieira et al. 1987). 
 
II.1.5.2.2 Hyperphage M13KO7∆pIII 
Hyperphage M13KO7∆pIII is a geneIII-deleted helperphage derivative of M13KO7. 
M13KO7∆pIII increases the percentage of recombinant phages carrying foreign proteins on 
their surface (Rondot et al. 2001). 
 
II.1.5.3 L540Cy cell line 
Human Hodgkin Lymphoma cell line L540Cy (Kapp et al. 1992) (DSMZ-Nr.: ACC 72) were 
used for isolation of total RNA (II.2.1.11.1) and for the amplification of the CD30 receptor 
encoding cDNA (II.2.1.11.2). 
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II.1.6 Buffer, media and solutions  
All standard solutions, buffers and media were prepared according to Sambrook et al. 
(1996), Ausubel et al. (1995) and Coligan et al. (1995). The non-standard solutions or buffers 
are listed at the end of the corresponding method description. Media for bacterial cultivation 
were sterilized by autoclaving (20min/121°C/1bar). Thermo labile components were filter 
sterilized by passing through a 0.2µm filter and added to the autoclaved media or buffer after 
they were cooled down to 50°C. 
 
II.1.7 Oligonucleotides 
Oligonucleotides used for the amplification or sequencing analysis are listed below. All 
oligonucleotides were synthesized by MWG Biotech (Ebersberg) or Biomers.net (Ulm) and 
HPLC purified. 
II.1.7.1 Oligonucleotides for construction and analysis of fd-g6m  
Name Sequence 
p-5’-BamHI 5’- ctg gct tta atg agg atc cat tcg -3’ 
p-3’-pVISfiI 5’- gga tgg ccg act tgg ccg atc cgc ctg agc ctc cac ctt tat ccc aat cca aat aag 
    aaa cg -3’ 
p-5’-pVINotI 5’- gat cgg cca agt cgg cca tcc cat atc acg cgg ccg cgt aaa tat ggc tgt tta ttt 
     tgt aac tg -3’ 
p-3’-PacI 5’- gta aat cgt cgc tat taa tta att ttc c -3’ 
p-5’-TS1-SeqI 5’- gcc atg tat gac gct tact g -3’ 
p-3’-TS1-SeqII 5’- gaa tta tca ccg tca ccg ac -3’ 
p-5’-TS1-SeqIII 5’- ctg cta tcg atg gtt tca ttg -3’ 
p-3’-TS1-SeqIV 5’- caa taa taa gag caa gaa aca atg -3’ 
p-5’-TS1-SeqV 5’- gag gtt cgc taa aac gcc tc -3’ 
p-3’-TS1-SeqVI 5’- ctg gaa aaa gcc tgt tta gtg -3’ 
p-5’-TS1-SeqVII 5’- cct act gtt gag cgt tgg c -3’ 
p-3’-TS1-SeqVIII 5’- gta cat aaa tca ata tat gtg atg -3’ 
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II.1.7.2 Oligonucleotides for construction and analysis of fd-g6/9m  
Name Sequence 
p-5’-BsrGI 5’- cgt atg cgc ctg gtc tgt aca c -3’ 
p-3’-pIXm 5’- acc gag cca ccg cca ccg cta gcc gag ccc tcg aga ctc atc ttt gac ccc cag 
     cg -3’ 
p-5’-pIXm 5’- tag cgg tgg cgg tgg ctc ggt ttt agt gta ttc ttt cgc ctc ttt c -3’ 
p-3’-BamHIb 5’- ctt gat att cac aaa cga atg gat c -3’ 
p-5’-BS2-SeqI 5’- gtc agg gca agc ctt att cac -3’ 
p-3’-BS2-SeqII 5’- ctt aaa cag ctt gat acc gat ag -3’ 
p-5’-BS2-SeqIII 5’- ctc agc gac cga ata tat cgg -3’ 
p-3’-BS2-SeqIV 5’- ggt gta tca ccg tact ca gg -3’ 
p-5’-BS2-SeqV 5’- cta tcc ctg aaa atg agg gtg -3’ 
p-3’-TS1-SeqII 5’- gaa tta tca ccg tca ccg ac -3’ 
 
II.1.7.3 Oligonucleotides for amplification of CD30R cDNA  
Name Sequence 
p-5’-CD30SfiI 5’- gtc ctc gca act gcg gcc agg tcg gcc cgc gtc ctc ctc gcc gcg c -3’ 
p-3’-CD30NotI 5’- cat gcg gcc gcc tta ctt ccc cgt gga gga gag agc -3’ 
p-5’-Seq-p6 5’- ctt ctg gta act ttg ttc ggc -3’ 
p-3’-Seq-p6 5’- cat gaa gaa acc aat caa taa tc -3’ 
 
II.1.7.4 Oligonucleotides for amplification of Ki-4(scFv) DNA 
Name Sequence 
p-5’-pIXKi4 5’- gtc ctc gca act gcg ctc gag gcc cag gtc aag ctg cag gag -3’ 
p-3’-pIXKi4 5’- gtc ctc gca act gct agc ccg ttt gat ttc cag ctt ggt gc -3’ 
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II.1.7.5 Oligonucleotides for construction and analysis of pHEN9 
Name Sequence 
p-5’-p9NotIa 5’- ata aga atg cgg ccg cag aac aaa aac tca tct cag aag agg atc tga atg  
     ggg -3’ 
p-5’-p9NotIb 5’- ctc aga aga gga tct gaa tgg ggc cgc ata gat gag tgt ttt agt gta ttc ttt cgc-3’ 
p-3’-p9EcoRI 5’- ccg gaa ttc tta tga gga agt ttc cat taa acg gg -3’ 
p-5’-pHENx 5’- cac aca gga aac agc tat gac c -3’ 
p-3’-pHENx 5’- caa ggc gat taa gtt ggg taa cg -3’ 
 
II.1.7.6 Oligonucleotides for construction of intermediate pHEN9-Bi 
Name Sequence 
p-5’-HindIII 5’- cgc caa gct tgc atg caa att ct -3’ 
p-3’-HEN39a 5’- gcc atc gcc ggc tga gcg gcg agt aat aac aat cca gcg g -3’ 
p-3’-HEN39b 5’- gat atc tct aga ctc gag ggc cat cgc cgg ctg agc gg -3’ 
p-5’-HEN39a 5’- gat atc ctg cag cca tgg gaa caa aaa ctc atc tca gaa gag gat c -3’ 
p-5’-HEN39b 5’- ggc cct cga gtc tag aga tat cct gca gcc atg gga ac -3’ 
p-3’-EcoRI 5’- cag tga att ctt atg agg aag ttt c -3’ 
 
II.1.7.7 Oligonucleotides for construction and analysis of pHEN3+9 
Name Sequence 
p-5’-HEN9Eco 5’- ccg gaa ttc gaa tgt gag tta gct cac tca tta g -3’ 
p-3’-HEN9Eco 5’- cgt gaa ttc tta tga gga agt ttc c -3’ 
p-5’-H39Seq 5’- cc acct tta tgt atg tat ttt cga c -3’ 
 
II.1.7.8 Oligonucleotides for sequencing of pHEN3CWP+9 
Name Sequence 
p-5’-biHEN3 5’- cga ctg gaa agc ggg cag tg -3’ 
p-3’-biHEN3 5’- ctg tat gag gtt ttg cta aac aac -3’ 
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II.1.7.9 Oligonucleotides for construction and analysis of pHEN3+9Strep 
Name Sequence 
p-5’-StrepIX 5’- ccc gca gtt cga aaa acc atg gga aca aaa act cat ctc -3’ 
p-3’-StrepIXa 5’- gtg gct cca gct agc ggc cat cgc cgg ctg agc -3’ 
p-3’-StrepIXb 5’- gtt ttt cga act gcg ggt ggc tcc agc tag cgg cc -3’ 
p-3’-biHEN9 5’- gcg aaa gaa tac act aaa aca ctc -3’ 
 
II.1.7.10  Oligonucleotides for construction and analysis of pHEN9-Strep 
Name Sequence 
p-3’-StrepI 5’- ctg cgg gtg gct cca gct agc ggc cat ggc cgg ctg ggc cgc -3’ 
p-3’-StrepII 5’- gtt ctg cgg ccg ctt ttt cga act gcg ggt ggc tcc agc tag -3’ 
p-5’-HENSeq 5’- gta tgt tgt gtg gaa ttg tga gcg -3’ 
 
II.1.8 Equipment 
Centrifuges:     AvantiTM 30, AllegraTM 6KR and MicrofugeTM (Beckman, California, USA), 
Eppendorf 5415D (Eppendorf, Hamburg). Rotors: Ja-10, Ja-30.50, JLA-16.250 (Beckman), 
F45-24-11 (Eppendorf). 
 
DNA gel electrophoresis apparatus:    wide mini and mini cells for DNA agarose 
electrophoresis and power suppliers (BioRad). 
 
DNA-sequencing:    „ABI Prism 3700“ Capillary-Sequencer (Perkin-Elmer, Applied 
Biosystems, Foster City, USA). 
 
Electron microscope: Transmission electron microscope EM-400T (Philips). 
 
Electroporation apparatus:    Gene pulser TM and Pulse controller unit (BioRad). 
 
ELISA-Reader:    ELISA-Reader SpectraMax 340 (Molecular Devices, München). 
 
Laminar flow:    Hera Safe HS12 (Kendro, Hanau). 
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PCR Thermocycler:    Primus 96 Plus (MWG-Biotech);  „Programmable Thermal Controller“ 
PTC-200™ (MJ Research Inc, Watertown, USA). 
 
Shaker incubator:   InnovaTM 4430 (New Brunswick Scientific, Nürtingen); 37°C incubator 
(Heraeus Instruments, Hanau); Eppendorf Thermomixer compact (Eppendorf). 
 
UV-Transilluminator:    302nm wavelength and UVT-20M (Herolab); UV-chamber (BioRad). 
 
Vortex:    Vortex Genie II (Scientific Industries Inc., Bohemia, USA). 
 
II.1.9 Approbation for the conducted work 
Permits for conducted work at security level S1 was given by the “Landesumweltamt NRW”. 
Number of registration is: 64-K-1.19/02. 
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II.2 Methods 
II.2.1 Recombinant DNA techniques 
General recombinant DNA techniques including DNA precipitation, restriction enzyme digest, 
DNA ligation and DNA agarose gel electrophoresis were performed according to the 
standard protocols described by Sambrook et al. (1996) or according to the manufacturer’s 
protocol when using a kit. 
 
II.2.1.1 Isolation of plasmid, phage and phagemid DNA from E. coli  
Plasmid, phagemid and phage DNA was purified using QIAprep® Plasmid Isolation Mini or 
Maxi Kit (II.1.2) according to the manufacturers’ manual. Quality and quantity of DNA was 
confirmed by spectrophotometric analysis (II.2.1.5) or analytical agarose gel electrophoresis 
(II.2.1.3). Isolated DNA samples were stored at –20°C. 
 
II.2.1.2 PCR amplification 
II.2.1.2.1 Standard PCR amplification of DNA fragments 
Polymerase chain reaction (PCR), a procedure for rapid in-vitro enzymatic amplification of a 
specific segment of DNA, was used for the amplification and modification of genes of interest 
Saiki et al. 1988) as well as for the insertion or deletion of restriction sites or short nucleotide 
sequences. The reactions were performed in 0.2ml PCR tubes (Biozym, Oldenburg), using a 
PCR thermocycler (MWG Biotech or MJ Research Inc.). PCR reactions were carried out in a 
total volume of 25µl as described in the following table: 
Components Volume Final concentration 
Template DNA 0.5-1µl 1-10ng 
10x PCR buffer 2.5µl 1x 
2,5M betain 2.5µl 250mM 
10mM dNTP mixture 1µl 0.4mM each 
100pmol/µl forward primer 1µl 10pmol/µl 
100pmol/µl backward primer 1µl 10pmol/µl 
Taq DNA polymerase (5U/µl) 0.25µl 1.25 units 
destilled water added to 25µl  
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Amplification was carried out under the following conditions: 
 95°C 5min initial denaturation 
 95°C 30sec denaturation 
             25x TP or gradient 30sec primer annealing 
 72°C 1min/1kb elongation 
 72°C 7min final elongation 
 
The optimal annealing temperature (TP) of the primer was experimentally optimized 
(temperature gradient) or calculated by the empirical formula (WU et al. 1991). 
TP = {22 + 1.046[2x(G +C) + (A + T)]} 
PCR products were resolved on a 1-1.2% (w/v) agarose gel (II.2.1.3) with appropriate DNA 
markers to confirm the successful amplification and integrity of the amplified product. 
 
II.2.1.2.2 SOE-PCR 
Splice overlap extension (SOE) PCR was used for insertion of the leader sequence, linker 
sequence, cloning sites or tags into the phage or phagemid vectors.  SOE PCR is a modified 
PCR method in which the primers are designed in a way that the coding region of the 3’ end 
of one primer is complementary to the 5’ region of the next primer (Horton et al. 1989).  
All modifications of phage or phagemid vectors were constructed by SOE PCR. First, two 
standard PCR’s (II.2.1.2.1) were carried out in order to amplify the DNA sequence upstream 
and downstream of the region, which had to be modified. By using appropriate primer the 
modified DNA sequence was fused to the 3’ end of the first (upstream) PCR product and to 
the 5’ end of the second (downstream) PCR product, respectively. The two resulting PCR 
products were assembled by SOE PCR using the inserted complementary sequences at 
their ends. Subsequently, the final SOE PCR constructs were cloned into the vectors of 
interest. 
SOE PCR was carried out with equimolar amounts of the two overlapping PCR fragments. 
Two reaction mixtures were prepared and SOE PCR was performed as described below: 
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Reaction mixture I: 
Components Volume Final concentration 
PCR product 1 1-3µl ~5ng 
PCR product 2 1-3µl ~5ng 
10x PCR buffer 2.5µl 1x 
2,5M betain 2.5µl 250mM 
10mM dNTP mixture 2µl 0.8mM each 
Taq DNA polymerase (5U/µl) 0.25µl 1.25 units 
destilled water added to 25µl  
 
Reaction mixture II: 
Components Volume Final concentration 
10x PCR buffer 2.5µl 1x 
2,5M betain 2.5µl 250mM 
10mM dNTP mixture 1µl 0.4mM each 
100pmol/µl forward primer (PCR1) 1µl 10pmol/µl 
100pmol/µl backward primer (PCR2) 1µl 10pmol/µl 
Taq DNA polymerase (5U/µl) 0.25µl 1.25 units 
destilled water added to 25µl  
 
Amplification was carried out under the following conditions: 
Reaction mixture I    
 95°C 5min initial denaturation 
 95°C 30sec denaturation 
                       7x TP or gradient 30sec annealing 
 72°C 1min/1kb elongation 
 72°C 5min final elongation 
 60°C forever  
Reaction mixture II was added    
 95°C 2min denaturation 
 95°C 45sec denaturation 
                       25x TP 45sec annealing 
 72°C 1min/1kb elongation 
 72°C 5min final elongation 
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II.2.1.2.3 PCR based analysis of recombinant bacterial clones 
Bacterial clones harboring plasmid DNA containing the gene of interest were identified by 
PCR as described by Jesnowski et al. (1995). Single colonies were picked with sterile 
toothpicks and dipped each in a PCR tube containing 10µl of sterile water. 15µl of the PCR 
mix (II.2.1.2.1) were added to each 10µl bacterial suspension giving a final volume of 25µl. 
Specific primers annealing to the 5’ and 3’ ends of the cloned gene or primers specific for the 
vector backbone were used for PCR reaction (II.2.1.2.1). Thermocycler conditions were used 
as described in II.2.1.2.1 but for effective lysis of the bacterial cells the time for initial 
denaturation was increased to 10 min. 10µl of the PCR product were analyzed on a 1.2% 
(w/v) agarose gel (II.2.1.3). 
II.2.1.3 Analytical agarose gel electrophoresis 
Undigested DNA (II.2.1.1), restriction enzyme digested DNA (II.2.1.6) and PCR fragments 
(II.2.1.2) were electrophoretically separated on 0.8-1.2% (w/v) agarose gels prepared in TAE 
buffer containing 0.1µg/ml ethidium bromide. 
Known amount of DNA molecular marker such as PstI-digested lambda DNA were used for 
evaluation of sample size, integrity and determination of DNA concentration. The DNA was 
visualized on an UV transilluminator at 302nm and documented by a black and white E.A.S.Y 
429K camera (Herolab). 
II.2.1.4 Preparative gel electrophoresis 
Preparative gel electrophoresis was used for isolation of PCR amplified DNA (II.2.1.2) or 
DNA fragments after restriction enzyme digestion (II.2.1.6) prior to cloning in the appropriate 
vectors. After electrophoresis the desired DNA fragments were excised from the gel and 
purified using the “QIAquick Gel Extraction Kit” (Qiagen) (II.2.1) according to the 
manufacturers’ protocol. The concentration of the recovered DNA was measured 
spectrophotometrically (II.2.1.5) or determined by analytical agarose gel electrophoresis 
(II.2.1.3). 
II.2.1.5 Quantification of nucleic acids 
The amount of RNA or DNA in a sample was estimated by measuring the OD260nm. The 
OD260nm of 1 corresponds to ~50µg/ml of dsDNA or ~40µg/ml of ssDNA and RNA. Purity of 
the nucleic acid was ascertained by the OD260nm/OD280nm ratio of the measured optical 
density, which is 1.8 for pure DNA and 2.0 for pure RNA. 
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II.2.1.6 Restriction digest of DNA 
Restriction endonucleases, corresponding buffers and BSA solution were obtained from New 
England Biolabs. Restriction digest and double restriction digest of DNA were performed 
according to the manufacturers’ protocol.  
II.2.1.7 Ligation of DNA 
Restriction enzyme digested DNA (II.2.1.6) was ligated by using the Quick LigationTM Kit from 
New England Biolabs. Ligation reactions were performed as recommended in the 
manufacturers’ protocol.   
II.2.1.8 Growth and maintenance of bacterial strains 
E. coli DH5α and XL1-Blue MR bacterial cells were grown at 37°C over night either in liquid 
LB medium in a shaker incubator or plated on solidified LB-agar [1.5% (w/v) agar] plates. E. 
coli TG1 were grown in 2xTY medium under the same conditions. The LB or 2xTY media 
were supplemented with appropriate antibiotics and 1% (w/v) glucose for the growth of 
recombinant bacteria. The plates were stored at 4°C for not more than two weeks. For long-
term storage of bacterial strains, glycerol was added to a final concentration of 15% (v/v) to 
the liquid culture and frozen at –80°C. 
II.2.1.9 Bacterial transformation 
II.2.1.9.1 Preparation of competent E. coli cells for heatshock transformation 
E.coli competent cells were prepared for CaCl2-mediated heatshock transformation as 
described by Hanahan (1983). Briefly, 5ml of LB broth were inoculated with a single bacterial 
colony and cultured at 37°C over night. 500µl of the over night culture was transferred into 
50ml of LB broth containing 20mM MgSO4 and 10mM KCl. The cells were cultured at 37°C 
for 3-4 h until the OD600nm reached 0.5 and then transferred to an ice-cold tube. After cooling 
on ice for 10min, the cells were recovered by centrifugation (2,000g/4°C/10min). The pellet 
was resuspended in 15ml ice-cold TfB-I solution by gentle vortexing and stored on ice for 
10min. The cells were sedimented down by centrifugation as described above and 
resuspended in 2ml ice-cold TfB-II. 100µl aliquots of the suspension were dispensed into 
prechilled 1.5ml Eppendorf tubes, frozen immediately in liquid nitrogen and stored at –80°C. 
TfB-I (pH 5.8): 30mM potassium acetate; 50mM MnCl2; 10mM CaCL2; 15% (v/v) glycerol  
TfB-II (pH 5.8): 30mM MOPS; 75mM CaCl2; 10mM RbCl; 15% (v/v) glycerol  
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II.2.1.9.2 Transformation of E. coli by heatshock 
Competent cells (II.2.1.9.1) were thawed on ice and ice-cold plasmid DNA (~80ng) or ligation 
product (II.2.1.7) were mixed gently with the competent cells and placed on ice for 30min. A 
heatshock of 42°C was given for 90sec and the sample was cooled on ice for two minutes. 
900µl SOC media, pre-heated at 37°C, were added to the sample and cells were incubated 
for regeneration at 37°C for 30min. 10µl and 100µl were plated onto LB or 2xTY agar plates 
supplemented with appropriate antibiotics and incubated at 37°C over night. 
II.2.1.9.3 Preparation of electrocompetent E. coli cells 
Electrocompetent E. coli cells were prepared for DNA transformation as described by Dower 
et al. (Dower et al. 1988). A single colony was cultured in LB broth at 37°C until the mid-log 
phase (OD600nm = 0.5-0.8). The cells were placed on ice for 30min prior to centrifugation 
(3,000g/4°C/10min). The harvested cells were subsequently washed thrice with ice-cold 
sterile water and resuspended in ice-cold 10% (v/v) glycerol resulting in a 300-fold 
concentration of the original culture volume (at >1010 cells/ml). 100µl aliquots were frozen 
immediately in liquid nitrogen and stored at –80°C. 
II.2.1.9.4 Transformation of E. coli by electroporation 
Eelectrocompetent cells (II.2.1.9.3) were thawed on ice and the cells were mixed with 80ng 
ice-cold DNA in sterile water. The cell/DNA mixture was transferred into a pre-chilled 
electroporation cuvette (0,1cm, BioRad) and assembled into the safety chamber of the 
electroporation apparatus. After application of a pulse (25µF, 1.7kV, 200Ω), the cells were 
diluted in 900µl pre-heated (37°C) SOC media and incubated for regeneration at 37°C for 
30min. 10µl and 100µl were plated onto LB or 2xTY agar plates supplemented with 
appropriate antibiotics and incubated at 37°C over night. 
II.2.1.9.5 Determination of transformation efficiency of competent cells  
Efficiency of transformation of each new batch of competent cells was determined by test 
transformation with known concentration of supercoiled DNA of pUC18. The following 
transformation rates were obtained: heatshock competent cells >108/µg pUC18 and 
electrocompetent cells >109/µg pUC18. 
II.2.1.10 DNA sequencing and sequencing analysis 
DNA sequencing reactions were based on the dideoxy chain termination method described 
by Sanger et al. (1977). Fluorescent labelled dideoxynucleotide were used for sequencing of 
genes or DNA fragments of interest. Sequencing analysis was performed by using an “ABI 
Prism 3700” Capillary-Sequencer (Applied Biosystems) and BigDyeTM cycle sequencing 
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terminator chemistry. The extension products were detected by exciting the unique dyes 
attached to each dideoxynucleotide with a laser, following by a measurement of fluorescent 
emission with a CCD camera. Subsequently, the signals were interpreted by the Applied 
Biosystems Sequencing Analysis Program in order to determine the nucleotide sequence of 
the DNA template. Chromas software package was used for displaying the chromatogram 
files. For evaluation of sequence data the sequences were exported to the DNAsis and GCG 
software packages. 
 
II.2.1.11 RNA isolation and synthesis of first-strand cDNA 
II.2.1.11.1 Total RNA extraction  
TRIzol® reagent (Invitrogen) was used for extraction of total RNA according to the 
manufacturers’ protocol. Briefly, 107 L540 cells (II.1.5.3) were lysed by resuspension in 1ml 
TRIzol® reagent followed by incubation of the homogenized cells at room temperature for 
5min. 0.2ml of chloroform (VWR) was added, followed by 15sec of vigorous shaking by hand 
and subsequent incubation for 3min at room temperature. After centrifugation 
(12,000g/4°C/15min) the colorless aqueous phase containing the RNA was transferred to a 
fresh tube. RNA was precipitated by incubation with 0.5ml of isopropanol (Roth) for 10min at 
room temperature and centrifuged (12,000g/4°C/10min). The RNA pellet was washed once 
with 75% (v/v) ethanol (Roth). The pellet was air dried for 5min and redissolved in 50µl 
RNAase free water. The purity and the amount of total RNA were estimated by 
spectrophotometric analysis (II.2.1.5). 
II.2.1.11.2 cDNA synthesis 
First-strand cDNA was synthesized by using the SuperScriptTM First-Strand Synthesis Kit 
(Invitrogen) and oligo-dT primer according to the manufacturers’ protocol. The cDNA primer 
p-5’-CD30Sfi and p-3’-CD30Not (II.1.7.3), which specifically anneal to the CD30-receptor 
(CD30R) encoding region were used for the amplification of first-strand cDNA (II.2.1.2.1).  
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II.2.2 Methods for phage analysis  
II.2.2.1 Phage amplification 
II.2.2.1.1 Phage amplification using phage vectors 
A 50ml 2xTY culture supplemented with tetracycline at a final concentration of 15µg/ml was 
inoculated with recombinant E. coli TG1 containing the appropriate phage vector and 
incubated over night at 30°C while shaking. The over night culture was centrifuged for 20min 
at 4,000g and the supernatant containing the assembled recombinant phages was used for 
phage preparation (II.2.2.2).  
II.2.2.1.2 Phage amplification using phagemid vectors 
A 50ml 2xTY culture supplemented with 1% (v/v) glucose and 100µg/ml ampicillin was 
inoculated with 500µl of an over night culture of recombinant E. coli TG1 containing the 
appropriate phagemid vector. The culture was inoculated at 37°C for 1.5-2.5 h while shaking. 
After OD600nm of 0.5 was reached, 5ml of the exponentially grown bacteria were transferred to 
a 50ml Falcon tube and 200µl helperphage M13KO7 (1011 phage/ml; II.1.5.2.1) or 
hyperphage M13KO7∆pIII (1011 phage/ml; II.1.5.2.2) were added immediately. For infection 
of the recombinant bacteria, the culture was incubated for 30min in a 37°C pre-heated water 
bath, following by 30min incubation at 37°C while shaking. After the infection process, the 
cells were spun down at 4,000g for 10min. The bacterial pellet was resuspended in 50ml 
(Midi preparation) or 500ml (Maxi preparation) 2xTY media supplemented with 100µg/ml 
ampicillin and 25µg/ml kanamycin and incubated at 30°C over night while shaking. The over 
night culture was centrifuged for 20min at 4,000g and the supernatant containing the 
assembled recombinant phages was used for phage preparation (II.2.2.2).  
II.2.2.2 Phage preparation 
1/6 volume of PEG/NaCl solution was added to the phages containing supernatant (II.2.2.1.1 
or II.2.2.1.2) and the solution was incubated for 4 h on ice. The precipitated recombinant 
phages were separated from the supernatant by centrifugation for 15min at 4,000g and 4°C. 
The phage pellet was resuspended in 1ml PBS (for Midi and Maxi preparation) and 
transferred to a fresh 1.5ml eppendorf tube. Remaining bacteria were removed by an 
additional centrifugation steps (14,000g/RT/2min). After the final centrifugation no bacterial 
pellet should be visible at all. The corresponding supernatant was transferred to a fresh 
eppendorf tube and stored at 4°C until further experiments. 
PEG/NaCl solution: 20% (w/v) polyethylene glycol 8000; 2.5M NaCl 
II Material and Methods 40
II.2.2.3 Phage titration 
Phage titration as well as phage titration ELISA (II.2.2.5.1) were used for quantification of 
prepared recombinant phages (II.2.2.2). The phage concentration was determined by 
transduction of E. coli TG1 with serial dilutions of the appropriate phage stock and 
subsequent counting of the colony forming units (cfu) of infected bacteria. Serial dilutions of 
the phage stock were titrated in 500µl of 2xTY media. To each dilution (10-2 – 10-12) 500µl 
exponentially growing E. coli TG1 were added and incubated at 37°C for 30min. After 
transduction of E. coli TG1, 100µl of the bacterial cells were plated on 2xTY plates 
supplemented with 100µg/ml ampicillin (for phagemid vector based phages, II.2.2.1.2) or 
15µg/ml tetracycline (for phage vector based phages, II.2.2.1.1). Plates were incubated over 
night at 30°C and after determination of the number of cfu the average phage titer was 
calculated. 
phage titer [phage/ml] = (number of cfu x 10 / dilution) x 200 
 
II.2.2.4 Purification of recombinant phages 
II.2.2.4.1 Purification of recombinant Strep-tag® displaying phages  
A new method was developed for the purification of recombinant phages displaying the 
Strep-tag® based on the Strep-tag® technology of IBA GmbH in Göttingen. IBA GmbH offers 
a well-established platform technology for expression, purification and detection of Strep-tag® 
fusion proteins (http://www.iba-bioTAGnology.com). The Strep-tag® is a short peptide 
consisting of 8 amino acids (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) binding specifically to the 
biotin binding pocket of streptavidin when fused to recombinant proteins. To optimize the 
binding properties IBA GmbH also engineered streptavidin to obtain Strep-Tactin®.  
Freshly prepared recombinant phages (Maxi prep; II.2.2.2) displaying the Strep-tag® either 
on pIII or pIX coat protein were purified by using Strep-Tactin® Superflow® cartridges (1ml 
column bed volume, IBA GmbH). The Strep-Tactin® cartridges were equilibrated by applying 
5ml Buffer W using a 10ml syringe at a flow rate of 1 drop/sec. Stock solution of freshly 
prepared phages was centrifuged (14,000g/RT/2min) and the cleared supernatant diluted 1:5 
with PBS before applying to the equilibrated Strep-Tactin® cartridge. Diluted supernatant was 
applied with a flow rate of not more than 0.5 drops/sec by using a 10ml syringe. Cartridges 
were washed with 5ml Buffer W and a flow rate of 1 drop/sec. Strep-tag® displaying phages 
were eluted by applying 3ml Buffer E containing the specific competitor desthiobiotin with a 
flow rate of not more than 0.5 drops/sec. The purified Strep-tag® displaying phages were 
stored at 4°C until further experiments.  
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For detection and analysis of these phages via Streptavidin or Strep-Tactin® Phage ELISA 
(II.2.2.5.3), the phages were dialyzed over night at 4°C in 2 liter Buffer E without desthiobiotin 
because remaining desthiobiotin is affecting the binding activity to streptavidin or Strep-
Tactin® coated microtiter plates. 
For regeneration of the Strep-Tactin® cartridges 2x 5ml Buffer W were applied with a flow 
rate of 1 drop/sec, followed by two injections of 5ml Buffer R using the same flow rate. 
Finally, the cartridges were washed with 2x 4ml Buffer W and stored at 4°C overlayed with 
1ml Buffer W. 
Buffer W: 100mM Tris-HCl; 150mM NaCl; 1mM EDTA; pH 8 
Buffer E: 100mM Tris-HCl; 150mM NaCl; 1mM EDTA; 2.5mM desthiobiotin; pH 8 
Buffer R: 100mM Tris-HCl; 150mM NaCl; 1mM EDTA; 1mM HABA (hydroxy-azophenyl-
benzoic acid), pH 8 
II.2.2.4.2 Purification of recombinant 6xHis-tag displaying phages 
According to II.2.2.4.1, a method for purification of recombinant phages displaying a 6xHis-
tag was developed. Freshly prepared recombinant phages (II.2.2.2) displaying a 6xHis-tag 
were purified using Ni-NTA Superflow® cartridges (1ml column bed volume, IBA GmbH). The 
Ni-NTA cartridges were equilibrated by applying 5ml Ni-NTA Lysis Buffer using a 10ml 
syringe at a flow rate of 1 drop/sec. Stock solution of freshly prepared phages was 
centrifuged (14,000g/RT/2min) and the cleared supernatant diluted 1:5 with PBS before 
applying to the equilibrated Ni-NTA cartridge. Diluted supernatant was applied with a flow 
rate of not more than 0.5 drops/sec using a 10ml syringe. Cartridges were washed with 5ml 
Ni-NTA Wash Buffer at a flow rate of 1 drop/sec. 6xHis-tag displaying phages were eluted by 
applying 3ml Ni-NTA Elution Buffer at a flow rate of not more than 0.5 drops/sec. The purified 
6xHis-tag displaying phages were stored at 4°C until further experiments.  
For regeneration, the Ni-NTA cartridges were washed as described by the manufacturer. 
Ni-NTA Lysis Buffer:  50mM NaH2PO4, 300mM NaCl, 10mM imidazol, pH 8 
Ni-NTA Wash Buffer:  50mM NaH2PO4, 300mM NaCl, 20mM imidazol, pH 8 
Ni-NTA Elution Buffer: 50mM NaH2PO4, 300mM NaCl, 250mM imidazol, pH 8 
II.2.2.4.3 Purification of bispecific phages 
According to II.2.2.4.1 and II.2.2.4.2, a method for purification of bispecific phages displaying 
a 6xHis-tag on pIII phage coat protein and a Strep-tag® on pIX phage coat protein was 
developed. Freshly prepared bispecific phages (II.2.2.2) displaying both tags were purified by 
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using a Ni-NTA Superflow® and a Strep-Tactin® Superflow® cartridge (each 1ml column bed 
volume, IBA GmbH). The Strep-Tactin® purification was carried out as described in II.2.2.4.1. 
The purified Strep-tag® displaying phages were collected in a sterile petri dish and directly 
applied to a pre-equilibrated Ni-NTA cartridge as described in II.2.2.4.2. The purified 
bispecific phages were stored at 4°C until further experiments.  
For detection and analysis of these phages via Streptavidin or Strep-Tactin® phage ELISA 
(II.2.2.5.3), the phages were dialyzed overnight at 4°C in 2 liter Buffer E (II.2.2.4.1) without 
desthiobiotin.  
Cartridges were regenerated as described in II.2.2.4.1 and II.2.2.4.2. 
II.2.2.5 Phage ELISA 
II.2.2.5.1 Phage Titration ELISA 
In addition to standard phage titration (II.2.2.3) the phage titration ELISA was used for 
quantification of prepared recombinant phages (II.2.2.2), especially to determine the 
concentration of phages prepared with the hyperphage M13KO7∆pIII (II.1.5.2.2) as the 
infectivity of these phages is highly decreased (Rondot et al. 2001 and O’Connell et al. 
2002). In contrast to the commercially available phage titration ELISA Kit from Progen 
Biotechnik GmbH (Heidelberg), the assay used within this thesis is based on a direct phage 
ELISA. Serial dilutions of the phage stock were directly coated on a 96-well high binding 
microtiter plate (Greiner) and detected by HRP-conjugated monoclonal antibodies specific for 
the phage major coat protein pVIII (II.1.3). The phage titer was determined by comparing the 
measured titration curves with the titration curve of a standard M13KO7 stock solution (1011 
phage/ml). The following conditions were used for phage titration ELISA:  
Step Concentration Vol. (µl/well)   Time (min) Temp. (°C) 
Coating serial dilution of phages in CB     150                 over night RT 
Blocking 2% (w/v) BSA in PBS 300                       60 RT 
HRP-antibody 1:2,000 in PBS + 0.5% (w/v) 
BSA 
100                        60 RT 
Substrate ABTS (Roche) 100                        15 RT 
CB (coating buffer, pH 9.6): 1.7ml of 0.2 M Na2CO3, 
    0.8ml of 0.2 M NaHCO3 
    7.5ml dest. H2O 
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All incubation steps were done while shaking the microtiter plates. After each incubation the 
plates were washed three times with PBS-T and PBS. 
II.2.2.5.2 Cell wall protein (CWP) phage ELISA 
Cell wall protein (CWP) phage ELISA was used for detecting recombinant phages displaying 
functional CWPD2 scFv antibody fragment (Peschen et al. 2004) either on the minor coat 
protein pIII or on pIX. CWP is a cell wall protein extract of fusarium and acts as antigen for 
the chicken scFv antibody fragment CWPD2 (Peschen et al. 2004). The following conditions 
were used for the CWP Phage ELISA:  
Step Concentration Vol. (µl/well)   Time (min) Temp. (°C) 
Coating CWP antigen 1:100 in PBS     150                 over night RT 
Blocking 2% (w/v) BSA in PBS 300                       60 RT 
Phages  serial dilution in PBS + 0.5% 
(w/v) BSA 
100                        60 RT 
HRP-antibody 1:2,000 in PBS + 0.5% (w/v) 
BSA 
100                        60 RT 
Substrate ABTS (Roche) 100                        15 RT 
CWP antigen was kindly provided by Dr. Dieter Peschen (RWTH Aachen, Department of 
Molecular Biology). All incubation steps were done while shaking the microtiter plates. After 
each incubation the plates were washed three times with PBS-T and PBS. 
II.2.2.5.3 Streptavidin or Strep-Tactin® phage ELISA 
Streptavidin or Strep-Tactin® phage ELISA were used for detection of Strep-tag® displaying 
recombinant phages. Streptavidin coated microtiter plates were obtained from Roche 
Diagnostics (Mannheim), whereas Strep-Tactin® coated ones were ordered from IBA GmbH 
(Göttingen). The following conditions were used for Streptavidin or Strep-Tactin® Phage 
ELISA:  
Step Concentration Vol. (µl/well)   Time (min) Temp. (°C) 
Blocking 2% (w/v) BSA in PBS 300                       60 RT 
Phages  serial dilution in PBS + 0.5% 
(w/v) BSA 
100                        60 RT 
HRP-antibody 1:2,000 in PBS + 0.5% (w/v) 
BSA 
100                        60 RT 
Substrate ABTS (Roche) 100                        15 RT 
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All incubation steps were done while shaking the microtiter plates. After each incubation the 
plates were washed three times with PBS-T and PBS. 
II.2.2.5.4 Biotin phage ELISA 
In contrast to the Streptavidin or Strep-Tactin® phage ELISA (II.2.2.5.3), the Biotin phage 
ELISA is an indirect assay used for detection of Strep-tag® displaying recombinant phages. 
Biotinylated microtiter plates were obtained from Pierce/Perbio (Bonn) and specific binding of 
Strep-tag® displaying phages was detected by using soluble unconjugated streptavidin 
(1mg/ml, Roche Diagnostics) or Strep-Tactin® (1mg/ml, IBA GmbH) as a linker molecule. The 
following conditions were used for Biotin phage ELISA:  
Step Concentration Vol. (µl/well)   Time (min) Temp. (°C) 
Blocking 2% (w/v) BSA in PBS 300                       60 RT 
Streptavidin or 
Strep-Tactin® 
1:1,000 in PBS + 0.5% (w/v) 
BSA 
100                       60 RT 
Phages  serial dilution in PBS + 0.5% 
(w/v) BSA 
100                        60 RT 
HRP-antibody 1:2,000 in PBS + 0.5% (w/v) 
BSA 
100                        60 RT 
Substrate ABTS (Roche) 100                        15 RT 
All incubation steps were done while shaking the microtiter plates. After each incubation the 
plates were washed three times with PBS-T and PBS. 
 
II.2.2.6 Electron microscopy 
Electron microscopy is a tool for structural (II.2.2.6.1) and immunological (II.2.2.6.2) analysis 
of recombinant filamentous bacteriophages. Samples for electron microscopy were prepared 
using Cu-grids (II.2.2.6.1) or Ni-grids (II.2.2.6.2) laminated with a pioloform-carbon support 
film. For electron microscopic analysis a transmission electron microscope EM-400 (Philips) 
was used. 
II.2.2.6.1 Adsorption compounds 
Adsorption compounds were prepared for morphological studies of the recombinant 
filamentous bacteriophages and their structural analysis by transmission electron 
microscopy. Freshly prepared recombinant phages (II.2.2.2) were diluted 1:10,000 in PBS 
and Cu-grids were floated for 15min on drops of this solution. The grids were washed with 20 
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drops PBS-T and blocked by floating on a drop of 0.5% (w/v) BSA in phosphate buffer (PB; 
pH7.2) for 30min at RT. Afterwards the grids were extensively washed with 40 drops PBS-T 
and 40 drops distilled water and stained with 6 drops of 1% (w/v) uranyl acetate for 
transmission electron microscopy.  
II.2.2.6.2 Immunogold assay 
Immunogold labelling (Louro & Lesemann, 1984) was used for detection and visualization of 
foreign proteins displayed on the surface of filamentous bacteriophages. Freshly prepared 
recombinant phages (II.2.2.2) were used to prepare adsorption compounds with Ni-grids 
instead of Cu-grids as described in II.2.2.5.3. After blocking the grids with 0.5% (w/v) BSA in 
PB (pH 7.2) primary antibodies (II.1.3) or binding proteins were bound to the samples by 
incubating the grids in a 1:500 PBS-T dilution of the appropriated antibody or Strep-Tactin® 
for 2 h at RT. The grids were washed twice with 20 drops PBS-T and incubated over night at 
RT with secondary gold-labelled antibodies (II.1.3) by floating the grid on a 1:50 PBS-T 
dilution. The grids were extensively washed with 40 drops PBS-T and 40 drops distilled water 
and stained with 6 drops of 1% (w/v) uranyl acetate for transmission electron microscopy. 
Two different set ups were used for immunogold labelling. 
First set up: 
 Step Concentration Time (min) Temp. (°C) 
Adsorption phages diluted 1:10,000 in PBS-T 15 RT 
Blocking 0.5% (w/v) BSA in PB (pH 7.2) 30 RT 
Primary antibody  1. Strep-tag® II specific mouse antibody 
    (II.1.3; IBA GmbH) 
2. polyclonal rabbit anti-6xHis 
   (II.1.3; Acris Antibodies) 
120 RT 
Secondary antibody 1. 15nm gold-conjugated goat anti-mouse 
    IgG (II.1.3; Biocell) 
2. 10nm gold-conjugated goat anti-rabbit 
    IgG (II.1.3; Biocell) 
over night RT 
Contrast 6 drops 1% (w/v) uranyl acetate - RT 
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Second set up: 
Step Concentration Time (min) Temp. (°C) 
Adsorption phages diluted 1:10,000 in PBS-T 15 RT 
Blocking 0.5% (w/v) BSA in PB (pH 7.2) 30 RT 
Primary antibody  1. mouse anti-penta-His, (II.1.3; Qiagen) 
2. horseradish peroxidase conjugated 
    Strep-Tactin® (IBA GmbH) 
120 RT 
Secondary antibody 1. 15nm gold-conjugated goat anti-mouse 
    IgG (II.1.3; Biocell) 
2. 10nm gold-conjugated goat anti-HRP  
    (II.1.3; Plano) 
over night RT 
Contrast 6 drops 1% (w/v) uranyl acetate - RT 
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III Results and Discussion 
This doctoral thesis was part of an interdisciplinary research project funded by the 
Fraunhofer Gesellschaft and was initiated to develop a novel protein microarray platform, 
called Protein Nanochip (Fig.I-9). As described in I.3.1, the Protein Nanochip should allow 
the automated screening of two phage libraries against each other in a high-throughput 
manner. A suitable chip surface structure and a laser detection system, both essential for the 
realization of the Protein Nanochip, had to be developed by other research partners involved 
in this project. Within this thesis a novel vector system for the generation of bispecific 
filamentous bacteriophages was developed. On the one hand these bispecific phages should 
allow the side-directed immobilization of a primary library onto the surface of the Protein 
Nanochip and on the other hand allow the binding of a secondary fluorescently labelled 
library, followed by detection, separation and analysis of specific binding partners. 
Two different strategies were developed for the generation of the bispecific filamentous 
bacteriophages. The first one was based on a phage vector system and the challenging task 
was to modify the fd-tet phage vector (Zacher et al. 1980) by inserting two cloning sites with 
appropriate linkers upstream of geneIX and downstream of geneVI. The results achieved 
with this strategy are shown and discussed in III.1. The second strategy was based on a 
phagemid vector system and describes the construction of a bispecific phagemid vector by 
modifying the well-characterized pHEN1 phagemid vector (Hoogenboom et al. 1991). The 
insertion of a second cloning cassette downstream of geneIII should allow the construction of 
the bispecific phagemid vector and the generation of bispecific phages. The results achieved 
using this strategy are shown and discussed in III.2. 
All phage and phagemid vectors created within this thesis are listed in V.2.1 and V.2.2.  
In addition a suitable technology for the side-directed immobilization of these bispecific 
phages onto the surface of the Protein Nanochip had to be developed. Appropriate strategies 
and the corresponding results are described in III.3. 
III.1 Construction and analysis of bispecific phage 
vectors 
The development of a bispecific phage vector system based on the fd-tet phage vector 
(Zacher et al. 1980) describes the first strategy for the generation of bispecific phages. This 
strategy was very challenging, because currently there are only phage vectors available 
which allow the display of foreign proteins as a pIII-fusion by cloning the corresponding gene 
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between the geneIII signal sequence and geneIII within the phage genome (Skerra et al. 
1988; Better et al. 1988). As described in I.1.2 there are only three regions, which were 
successfully used for modifications of the phage genome, leading to the correct assembly of 
functional phages. Modifications of the phage genome were tolerated within the intergenic 
region, within the small region between the end of geneVIII and the beginning of geneIII as 
well as between geneIII leader and geneIII (Zacher et al. 1980; McCafferty et al. 1990; 
Clackson et al. 1991). In addition there appears to be a delicate balance in the synthesis of 
modified phage proteins that allows phage production without seriously affecting bacterial 
growth (Model and Russel 1988; Webster 1996). These observations indicate that the 
transcription and translation of the phage genome is highly regulated and can be interpreted 
in a way that successful genetical modifications of the phage genome are challenging.  
Nevertheless, the construction of a bispecific phage vector system had been one of the 
objectives of the presented work. This strategy was chosen because phage vectors allow 
multivalent display of foreign proteins on their surface, whereas phagemid vectors lead to 
monovalent display (Marks et al. 1992; O’Connell et al. 2002). Multivalent display of a 
repertoire of proteins induces an avidity effect resulting in higher binding activity between two 
binding phages and thus would facilitate the separation and sorting of these phage pairs. In 
addition, the tetrameric streptavidin molecule needed to be used for phage immobilization on 
biotinylated chip surfaces and thus multivalent display of streptavidin monomers was 
necessary. A disadvantage of this system is the decreased infectivity of rescued phages, due 
to the fact that currently only pIII phage vectors are available and that at least one 
incorporated wild type pIII copy is necessary for each phage to be infectious (I.1.3). 
Therefore a novel pVI phage vector had to be designed based on the data shown by Jespers 
et al. (Jespers et al. 1995). Previously, coat protein pVI had not been described to be 
involved in the infection process and therefore the modification of geneVI should not affect 
the infectivity of the corresponding phages. Originally, the pVI phagemid system was 
developed for the screening of full-length cDNA libraries, because the stop codon of the 
cDNAs is not affecting the expression of the cDNA-pVI fusion proteins when cloned to the 3’-
end of geneVI. Therefore, establishing a bispecific phage vector based on the pVI-display 
system would not only circumvent the infectivity problem but also allow the library display on 
the same side of the phage as in the pIII-system. In addition, it should be possible to use pVI 
for the display of different kinds of protein libraries including cDNA libraries. For integration of 
the second specificity the phage coat protein pIX was the display system of choice, because 
it had been shown that pIX-display is the better screening system compared to pVII (Gao et 
al. 2003; Endemann and Model 1995).  
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III.1.1 Construction of bispecific phage vector fd-g6/9m 
The bispecific phage vector fd-g6/9m was cloned by insertion of two cloning sites and 
appropriate linker sequences. For the construction of this bispecific phage vector the 
intermediate fd-g6m was cloned first. The corresponding cloning strategy is shown in Fig.III-
1. According to Jespers et al. (Jespers et al. 1995) a G3SG2-linker sequence as well as a 
SfiI/NotI-restriction site were inserted downstream of geneVI within the fd-tet phage vector 
(Zacher et al. 1980) using SOE-PCR. 
 
Fig.III-1: Cloning strategy for the construction of intermediate fd-g6m. p-5’-BamHI: 
forward primer for the amplification of amplicon A; p-3’-pVISfi: backward primer for the 
amplification of amplicon A and for insertion of the G3SG2-linker sequence (Jespers et al. 
1995) and a SfiI-restriction site at the 3’-end of geneVI; p-5’-pVINot: forward primer for the 
amplification of amplicon B and for insertion of a G3SG2-linker sequence and a SfiI/NotI-
cloning site at the 5’-end of geneI/X; p-3’-PacI: backward primer for the amplification of 
amplicon B. Amplicon A and B were assembled using SOE-PCR (II.2.1.2.2) and subsequently 
cloned into BamHI/PacI-digested fd-tet phage vector (Zacher et al. 1980). 
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Fd-g6m intermediate was used for the construction of the bispecific phage vector fd-g6/9m 
and the corresponding cloning strategy is shown in Fig.III-2. According to Gao et al. (Gao et 
al. 1999) a G4S-linker sequence as well as a XhoI/NheI-restriction site were inserted 
downstream of the second triplet of geneIX within the fd-g6m intermediate (Fig.III-1) using 
SOE-PCR (II.2.1.2.2). Insertion at this position was necessary because the 3’-end of geneVII 
and 5’beginning of geneIX are overlapping (Blumer et al. 1987; Ivey-Hoyle and Steege 1989) 
and any alteration of regulatory elements had to be avoided. 
          
Fig.III-2: Cloning strategy for the construction of the bispecific phage vector fd-g6/9m. p-
5’-BsrGI: forward primer for the amplification of amplicon A; p-3’-pIXm: backward primer for the 
amplification of amplicon A and for insertion of a G4S-linker sequence (Gao et al. 2002b) and a 
XhoI/NheI-cloning site downstream the second triplet of geneIX; p-5’-pIXm: forward primer for 
the amplification of amplicon B and for insertion of a G4S-linker sequence and a XhoI/NheI-
cloning site behind the second triplet of geneIX; p-3’-BamHIb: backward primer for the 
amplification of amplicon B. Amplicon A and B were assembled using SOE-PCR (II.2.1.2.2) and 
subsequently cloned into BsrGI/BamHI-digested intermediate phage vector fd-g6m (Fig.III-1). 
Sequencing analysis (II.2.1.10) was done using primers p-5’-BS2-SeqI, p-3’-BS2-SeqII, p-5’-
BS2-SeqIII, p-3’-BS2-SeqIV, p-5’-BS2-SeqV and p-3’-TS1-SeqII (II.1.7.1 and II.1.7.2). 
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III.1.2 Analysis of bispecific phage vector fd-g6/9m 
The CD30R cDNA encoding the extracellular domain of the human CD30 receptor was 
cloned as fusion to geneVI in order to verify the functionality of the bispecific phage vector fd-
g6/9m (Fig.III-2). The cloning strategy for the construction of fd-g6CD30/9m is shown in 
Fig.III-3. CD30R cDNA was amplified using total RNA extracted from the human cell line 
L540Cy (II.1.5.3) and primers p-5’-CD30SfiI and p-3’-CD30NotI (II.1.7.3; II.2.1.11.2). 
Restriction sites were fused to the ends of the CD30R cDNA and cloned in the SfiI/NotI-
cloning site upstream of geneVI.  
         
Fig.III-3: Cloning strategy for the construction of fd-g6CD30/9m. Total RNA (II.2.1.11.1) 
isolated from L540Cy cells (II.1.5.3) were used for first-strand cDNA synthesis (II.2.1.11.2). 
First-strand cDNA was used as a template for the amplification of the DNA sequence encoding 
for the open reading frame of the extracellular domain of the human CD30 receptor (CD30R). 
p-5’-CD30SfiI (II.1.7.3): forward primer for the amplification of CD30R cDNA and for insertion 
of a SfiI-restriction site at the 5’-end of this sequence; p-3’-CD30NotI (II.1.7.3): backward 
primer for the amplification of CD30R cDNA and for insertion of a NotI-restriction site at the 3’-
end of this sequence. Amplified CD30R cDNA was cloned into SfiI/NotI-digested fd-g6/9 
phage vector (Fig.III-2). Sequencing analysis (II.2.1.10) was done using primers p-5’-Seq-p6 
and p-3’-Seq-p6 (II.1.7.3). 
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The fd-g6CD30/9m phage vector was transformed into E. coli TG1 and freshly prepared 
phage particles (II.2.2.2) were analyzed in order to prove their infectivity. As described 
above, the infectivity should not be affected in any way by multivalent display of the CD30R 
on the pVI coat protein. However, due to the fact that pVI is located at the same end of the 
phage as pIII, there was a chance that phage infectivity would decrease due to steric 
problems and therefore the infectivity had to be investigated. Phages were used to infect E. 
coli TG1 and subsequently twelve tetracycline resistant colonies were analyzed for the 
presence of the CD30R cDNA by colony PCR (II.2.1.2.3) using primers p-5’-Seq-p6 and p-3’-
Seq-p6. The results are shown in Fig.III-4. 
     
Fig.III-4: Colony PCR of E.coli TG1 infected with fd-g6CD30/9m phages. In order to 
prove the infectivity of fd-g6CD30/9m phages, E. coli TG1 were infected with phages as 
described in II.2.2.3 and tetracycline resistant clones were used for PCR analysis 
(II.2.1.2.3) using primers p-5’-Seq-p6 and p-3’-Seq-p6 (II.1.7.3). λ: PstI-digested lambda 
DNA; fd-tet: E. coli TG1 containing fd-tet phage vector were used as a control for the 
colony PCR; fd-g6CD30/9m: 12 clones of E. coli TG1 infected with fd-g6CD30/9m phages 
used for colony PCR analysis; pc: fd-g6CD30/9m DNA used as a positive control for PCR 
analysis, showing the size of PCR products containing the CD30 receptor cDNA (1811bp); 
nc: fd-g6/9m DNA used as a negative control for PCR analysis, showing the size of PCR 
products not containing the CD30 receptor cDNA (684bp). 
Ten out of the twelve clones tested, contained fd-g6CD30/9m and thus confirmed the 
presence of the CD30R cDNA within the phage vector. Therefore, the infectivity of the fd-
g6CD30/9m phages was clearly demonstrated. Moreover, they were displaying five copies of 
the large extracellular domain of the human CD30R on pVI. In conclusion phage vectors can 
be designed for pVI-display of foreign proteins without affecting their infectivity.  
To confirm the correct assembly and therefore the right morphology of the CD30R displaying 
phages an electron microscopical analysis (II.2.2.6) was performed and the corresponding 
results are shown in Fig.III-5. 
fd-tet fd-g6CD39/9m 
pc  nc 
CD30R + 
CD30R - 
λ λ 1     2      3      4     5      6      7      8      9     10    11   12 
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Fig.III-5: Electron microscopical analysis of fd-g6CD30/9m phages: The morphology of 
CD30R-displaying phages (fd-g6CD30/9m) was analyzed by electron microscopy. Phages 
(II.2.2.2) were immobilized on Cu-grids (II.2.2.6.1) and analyzed using an EM-400 electron 
microscope (Philips) with 60kV and a magnification of 130.000x.  
In comparison to wild type fd phages (Fig.I-2) the morphology of fd-g6CD30/9m phages 
seems to be homologous. However, phage preparations for the infectivity assay (Fig.III-4) 
and for the electron microscopy (Fig.III-5) indicated decreased assembly efficiency, although 
all phages were infectious and showed the “correct” morphology. To further investigate this 
observation the assembly efficiency of fd-g6CD30/9m phages was determined by phage 
titration (Fig.III-6). 
 phages assembly efficiency [cfu/ml] 
fd-tet 8.31 x 1014 
fd-g6m 1.23 x 108 
fd-g6/9m 1.02 x 108 
fd-g6CD30/9m 4.47 x 107 
no phages 0 
Fig.III-6: Assembly efficiency of the modified phage vectors. Assembly efficiencies of 
all modified phage vectors were determined by a phage titration assay (II.2.2.3). The data 
were acquired in triplicate and the mean assembly efficiency (cfu/ml) calculated. Fd-tet: 
original phage vector (Zacher et al. 1980); fd-g6m: intermediate phage vector (Fig.III-1); fd-
g6/9m: bispecific phage vector (Fig.III-2); fd-g6CD30/9m; bispecific phage vector 
containing CD30R cDNA fused to geneVI (Fig.III-3); no phages: E. coli TG1 incubated with 
2xTY media without phages. 
 
100nm 
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The results shown in Fig.III-6 confirmed that the assembly efficiency of the fd-g6CD30/9m 
phages was dramatically decreased. Twenty million times less of these phages were 
produced in comparison to unmodified fd-tet phages. Surprisingly, the decreased assembly 
efficiency was mainly due to geneVI modification itself and not to the insertion of the CD30R 
cDNA into the bispecific fd-g6/9m phage vector, as expected. Inserting the G3SG2-linker 
sequence and the SfiI/NotI-restriction site downstream of geneVI (Fig.III-1) decreased the 
assembly efficiency about 7x106 times. Nevertheless, 4x107 CD30R-displaying phages were 
produced, maintaining their infectivity and featuring the “correct” morphology. 
In conclusion the geneVI modification of the fd-tet phage vector, which was done according 
to Jespers et al. (1995), dramatically affected the assembly efficiency of the corresponding 
phages. The most obvious reason might be a steric problem that occurs by multivalent 
display of the large CD30R cDNA as fusion to the pVI coat protein. The resulting protein 
cluster at the end of the phages could prevent the release of the phage particles from the 
bacterial membrane because the channels, which are formed by phage protein pIV, pI and 
pXI, are only 8nm in diameter and therefore could be clogged by the phage. pVI coat protein 
is much smaller than pIII and therefore the higher flexibility of pIII could explain its capability 
for multivalent display of foreign proteins on the surface of filamentous bacteriophages 
causing just slight decreased assembly efficiency (O’Connell et al. 2002). But the insertion of 
the CD30R cDNA did not seem to be the main reason for the assembly problem of the 
bispecific phage vector fd-g6/9m. The insertion of the G3SG2-linker sequence and the 
SfiI/NotI-restriction site to geneVI might have caused this problem. If insertion of these few 
amino acids to the 3’-end of geneVI was enough to cause a steric problem or if there are any 
other reasons for the loss of assembly efficiency can only be speculated on and has not 
been experimentally determined due to time constrains. Nevertheless, 4x107 CD30R-
displaying phages were produced, maintaining their infectivity and featuring the “correct” 
morphology. In conclusion, geneVI modification can be used for multivalent display of foreign 
proteins and for the generation of small libraries with a maximum diversity of about 107. 
Modification of geneIX and insertion of the CD30R cDNA seemed not to be responsible for 
the decrease of the assembly efficiency, because bispecific fd-g6/9m phage vector showed 
the same efficiency as fd-g6m.  
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III.1.3 Construction and analysis of phage vector fd-g9m 
III.1.3.1 Construction of phage vector fd-g9m 
Although the above mentioned results show a decreased assembly efficiency resulting in 
protein libraries with a limited diversity, the use of a phage vector system could still be 
feasible by using geneIII instead of geneVI. GeneIII has already been described in the 
literature to be a suitable display system (Zacher et al. 1980; Smith et al. 1985; Clackson et 
al. 1991; O’Connell et al. 2002). In addition, it should be possible to display full-length 
cDNA’s on pIII coat protein by employing the Fos/Jun technology described by Crameri and 
Suter (Crameri and Suter 1993). According to their strategy, the described Jun-sequence 
had to be fused to geneIII and in addition an expression cassette had to be inserted into e.g. 
the intergenic region of the phage vector containing a pelB signal sequence, the Fos-
sequence and a cloning cassette for insertion of the cDNA sequences. The pelB/Fos/cDNA 
fusion proteins would be directed to the periplasm of the bacterial host and should be 
incorporated into the phage by forming a leucin zipper with the Jun/pIII fusion protein. 
Before establishing this cDNA display system it had to be proven that geneIX can be used for 
multivalent display of foreign proteins. Especially the modification of geneIX was expected to 
be critical because the 3’-end of geneVII and 5’-end of geneIX are overlapping and 
transcription, RNA processing and translation of these genes are somehow coupled to 
geneV and geneVIII. These four adjacent genes are transcribed to a polycystronic mRNA 
encoding pV, pVII, pIX and pVIII coat proteins and the different expression levels of the 
highly expressed pV and pVIII coat proteins and the rarely expressed pVII and pIX coat 
proteins have been explained due to local secondary structures of the mRNA at the transition 
from geneV to geneVII and by translation initiation sites showing differences in their activity 
(Blumer et al. 1987; Ivey-Hoyle and Steege 1989; Ivey-Hoyle and Steege 1992; Stump and 
Steege 1996). Whereas, the ribosome binding sites of geneVII appears to be limited mainly 
due to the local mRNA structure, no interaction of ribosomes with the corresponding binding 
site of geneIX has been proven at all and the appropriate regulatory elements have not been 
described up to now. Knowing at least some of these regulatory elements, the position for 
modification of geneIX was determined as the one between its second and third triplet, 
hopefully not destroying any regulatory mechanism within the transition of geneVII and 
geneIX. To verifiy this assumption the phage vector fd-g9m was constructed carrying the 
geneIX modification of fd-g6/9m without modification of geneVI. The corresponding cloning 
strategy is shown in Fig.III-7. According to Gao et al. (1999) fd-g9m was generated by 
inserting a G4S-linker sequence as well as an XhoI/NheI-restriction site downstream of the 
second triplet of geneIX within the fd-tet phage vector (Zacher et al. 1980). 
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Fig.III-7: Cloning strategy for the construction of phage vector fd-g9m. p-5’-BsrGI: forward 
primer for the amplification of amplicon A; p-3’-pIXm: backward primer for the amplification of 
amplicon A and for insertion of a G4S linker (Gao et al. 2002b) and a XhoI/NheI-cloning site 
behind the second triplet of geneIX; p-5’-pIXm: forward primer for the amplification of amplicon 
B and for insertion of a G4S linker and a XhoI/NheI-cloning site behind the second triplet of 
geneIX; p-3’-BamHIb: backward primer for the amplification of amplicon B. Amplicon A and B 
were assembled using SOE-PCR (II.2.1.2.2) and subsequently cloned into BsrGI/BamHI-
digested phage vector fd-tet (Zacher et al 1980). Sequencing analysis (II.2.1.10) was done 
using primers p-5’-BS2-SeqI, p-3’-BS2-SeqII, p-5’-BS2-SeqIII, p-3’-BS2-SeqIV, p-5’-BS2-SeqV 
and p-3’-TS1-SeqII (II.1.7.1 and II.1.7.2). 
 
III.1.3.2 Analysis of phage vector fd-g9m 
The Ki-4(scFv) cDNA encoding the CD30 receptor specific single chain antibody Ki-4 (Barth 
et al. 2000) was cloned as a fusion upstream of geneIX in order to verify the functionality of 
the phage vector fd-g9m (Fig.III-7; Fig.III-8). Ki-4(scFv) DNA was amplified using the 
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prokaryotic expression vector pMT-Ki4-ETA (Barth et al. 2000) as a template and primers p-
5’-pIXKi4 and p-3’-pIXKi4 (II.1.7.4; II.2.1.11.2). Suitable restriction sites were incorporated for 
subsequent cloning into the XhoI/NheI-cloning site of geneIX. 
                          
Fig.III-8: Cloning strategy for the construction of fd-g9Ki4. Ki-4(scFv) DNA was amplified 
using the prokaryotic expression vector pMT-Ki4-ETA as a template (provided by Dr. M. K. 
Tur, Fraunhofer IME Aachen; Barth et al. 2000) and primer p-5’-pIXKi4 as well as primer p-3’-
pIXKi4 (II.1.7.4). p-5’-pIXKi4: forward primer for the amplification of Ki-4(scFv) open reading 
frame and for insertion of a XhoI-restriction site at the 5’-end of this sequence; p-3’-pIXKi4: 
backward primer for the amplification of Ki-4(scFv) open reading frame and for insertion of a 
NheI-restriction site at the 3’-end of this sequence. Amplified Ki-4(scFv) DNA was cloned into 
XhoI/NheI-digested fd-g9m phage vector (Fig.III-7). Sequencing analysis (II.2.1.10) was done 
using primers p-5’-BS2-SeqI and p-3’-BS2-SeqII (II.1.7.2). 
 
The influence of the geneIX modification on the assembly efficiency of fd-g9m and fd-g9Ki4 
phages was determined by phage titration (Fig.III-9).  
 
 
 
 
Ki-4(scFv) 
XhoI NheI 
G4S gene VII 
fd-g9Ki4 
gene IX Ki-4(scFv) 
XhoI NheI 
PCR 
p-5‘-pIXKi4 
p-3‘-pIXKi4 
  Ki-4(scFv) 
pMT-Ki4-ETA 
XhoI/NheI 
gene VII 
fd-g9m 
gene IX G4S 
Restriction with  
XhoI/NheI 
Restriction with  
XhoI/NheI 
III Results and Discussion 58
phages assembly efficiency [cfu/ml] 
fd-tet 6.67 x 1014 
fd-g9m 5.84 x 1011 
fd-g9Ki4 0 
no phages 0 
Fig.III-9: Assembly efficiency of modified phage vectors. Assembly efficiencies of 
geneIX modified phage vectors were determined by a phage titration assay (II.2.2.3). The 
data were acquired in triplicate and the mean assembly efficiency (cfu/ml) was determined. 
Fd-tet: original phage vector (Zacher et al. 1980); fd-g9m: pIX-display phage vector (Fig.III-
7); fd-g9Ki4; pIX-display phage vector containing Ki-4(scFv) DNA within the pIX-cloning 
site (Fig.III-8); no phages: E. coli TG1 incubated with 2xTY media without phages.  
Contrary to all expectations, the modification of geneIX by inserting a G4S-linker sequence 
and a XhoI/NheI-restriction site behind the second triplet within phage vector fd-tet leads only 
to a 1000x decreased assembly efficiency (Fig.III-9) compared to fd-tet, which would be 
tolerable for a library construction possessing a sufficient diversity of about 1011.  
Surprisingly, no phages could be produced at all after insertion of the Ki-4(scFv) cDNA (Barth 
et al. 2000) into the geneIX cloning site because fd-g9Ki4  (Fig.III-8) transformed E.coli TG1 
bacteria could not be cultivated in liquid media. It was not possible to inoculate liquid media 
by picking these bacteria from plates. Nevertheless colony PCR (II.2.1.2.3) and sequencing 
analysis (II.2.1.10) confirmed the integrity of these fd-g9Ki4 transformed E. coli TG1 bacteria. 
This lethal effect of expressed Ki-4(scFv)/pIX fusion proteins for the bacterial host could be 
explained by the observations of Model and Russel as well as by Webster, who claim that 
there is a delicate balance in the synthesis of modified phage proteins that allow phage 
production without seriously affecting bacterial growth (Model and Russel 1988, Webster 
1996). Due to the fact that the Ki-4(scFv)/pIX fusion proteins did not cause a lethal effect 
when being encoded by a phagemid vector, there could be just a limitation in the size of the 
foreign protein or peptide being multivalently displayed on pIX coat protein. Nevertheless, 
Gao et al. (Gao et al. 2002) and the results shown in Fig.III-12 prove functional monovalent 
display of single chain antibody fragments on pIX coat protein using a phagemid vector, a 
lethal effect may occur when the same scFv/pIX-fusion proteins is encoded by a phage 
vector. The incorporation of the 30kDa scFv/pIX-fusion protein during the assembly process 
in the absence of wild type pIX coat proteins may lead to this lethal effect. Perhaps, the 
pI/pIX/pIV-channels are damaged within the host membrane due to the size of the five 
scFv/pIX-fusion proteins that have to be incorporated within one phage particle in 
comparison to the incorporation of just one of these fusion proteins together with four wild 
type pIX proteins in a phagemid system (Guy-Caffey and Webster 1993; Webster 1995; 
Kazmiercak et al. 1994; Linderoth et al. 1997). Thus the essential membrane potential could 
not be maintained causing the death of the bacterial host. This lethal effect will not occur by 
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multivalent display of small peptides because the display of the nine amino acids encoded by 
the G4S-linker sequence and the XhoI/NheI-restriction site on pIX coat protein only leads to a 
1000-fold decrease of the assembly efficiency and no lethal effect was observed (fd-g9m; 
Fig.III-7; Fig.III-9). In conclusion, geneIX modification can be used for multivalent display of 
foreign peptides on the surface of filamentous bacteriophages and for the generation of 
peptide libraries encoding up to nine amino acid residues to provide a diversity of about 1011. 
Summary of the results obtained with modified phage vectors: 
• GeneVI modified phages showed six million times decreased assembly efficiency 
caused by the insertion of the G3SG2-linker sequence and the SfiI/NotI-restriction site. 
• Modification of geneVI and insertion of the CD30R cDNA into its cloning site resulted 
in 4.47x107 infectious phages per ml all featuring the “correct” morphology, which 
would be suitable for construction of immunized protein libraries. 
• Modification of geneIX by insertion of a G4S-linker sequence and an XhoI/NheI-
restriction site downstream of its second triplet decreases the assembly efficiency 
1000-fold, which would be suitable for construction of peptide libraries.  
• Insertion of the Ki-4(scFv) DNA into the geneIX cloning site abolished the phage 
assembly due to a lethal effect on the bacterial host, which cannot be grown in liquid 
culture. 
There might be an option for generating bispecific filamentous bacteriophages using a 
pVI/pIX-phage vector system but with a limitation in the size of corresponding libraries 
displayed on pVI coat protein. The construction of a pIII/pIX-phage vector based on for 
example phage vector fd-tet-DOG1 (Clackson et al. 1991) might be a better alternative. 
Phage vector fd-tet-DOG1 possesses the capability for multivalent display of foreign proteins 
on pIII coat protein and by insertion of DNA sequences downstream of the second triplet of 
geneIX encoding for small peptides which are no longer than nine amino acids it should be 
possible to generate bispecific phages. These bispecific phages could display a protein 
library fused to pIII coat protein and any peptide motif of interest on the opposite site of the 
phage as fusion to the pIX coat protein. Unfortunately, due to time constrains it was not 
possible to verify this hypothesis.  
However, in addition to this first phage vector based strategy for the generation of bispecific 
filamentous bacteriophages a second strategy was developed based on a bispecific 
phagemid vector system. The cloning strategies and results are described in III.2. 
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III.2 Construction and analysis of bispecific phagemids 
Due to the assembly problems of phages produced using modified phage vectors (III.1), a 
new strategy for the generation of bispecific bacteriophages was developed. A bispecific 
phagemid vector was generated based on the pHENHi phagemid vector (Peschen et al. 
2004) a derivative of the well-characterized pHEN1 phagemid vector (Hoogenboom et al. 
1991) containing an additional 6xHis-tag and a modified 218 poly-linker (II.1.4.2.2). This 
bispecific phagemid vector should allow the monovalent display of: 
a. library proteins on pIII coat protein 
b. proteins or peptides for immobilization on biotinylated surfaces or labelling as a 
fusion to the pIX coat protein 
Coat protein pIII was chosen because of the assembly problems encountered by the pVI-
display system (III.1), which might also be the case when using a phagemid vector. So far 
only Jespers (Jespers et al. 1995) published data on the pVI-display system. For the 
construction of full-length cDNA libraries, pIII can be used by adapting the Fos/Jun-system 
as described by Crameri and Suter (Crameri and Suter 1993).  
For the integration of the second specificity the phage coat protein pIX was selected as the 
display system of choice, because pIX-display has been shown to be the better screening 
system compared to pVII (Gao et al. 2003; Endemann and Model 1995). The final bispecific 
phagemid vector pHEN3+9 (Fig.III-14) was generated by insertion of a complete second 
expression cassette containing geneIX downstream of the already existing one within the 
pHENHi phagemid vector (Peschen et al. 2004). This second expression cassette was 
designed in a way that it is compatible to the first one. Therefore, a new multi cloning site 
(MCS, Fig.III-14) was synthesized and fused to geneIX using a G4S-linker sequence in 
between. Transcription and translation of the additional expression cassette was regulated 
by a lac-promoter/operator and a ribosome binding site, according to the regulatory elements 
within the first expression cassette of phagemid vector pHENHi in order to achieve an 
equimolar expression level of the pIII- and pIX-fusion proteins. This vector design was 
chosen following the principle of the commercially available and well-characterized 
pETDuetTM-1 vector (Novagen) generated for prokaryotic coexpression of two different target 
genes. This pETDuetTM-1 vector also contains two different multi cloning sites, each of which 
is proceeded by the same regulatory elements, which in particular are two T7-promoters and 
lac-operators combined with the same ribosome binding site. The final bispecific pHEN3+9 
phagemid (Fig.III-14) should allow the bacterial expression of pIII- and pIX-fusion proteins in 
parallel and thus the assembly of bispecific bacteriophages by incorporation of these 
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recombinant proteins into the phage particles after infection of the bacteria with a 
helperphage.  
Due to the lethal effect observed on bacterial cells transformed with the fd-g9Ki4 phage 
vector (Fig.III-9), the integrity of the pIX-display system was investigated before assembling 
the bispecific phagemid vector pHEN3+9 
 
III.2.1 Construction and analysis of phagemid vector pHEN9 
III.2.1.1 Construction of phagemid vector pHEN9 
According to Gao et al., who is the only one publishing data on the pIX-display system (Gao 
et al. 1999; Gao et al. 2002a; Gao et al. 2002b; Gao et al. 2003) and in consideration of the 
experiences with the modified phage vectors (III.1), the pIX-system had to be investigated 
before being used for cloning the bispecific phagemid vector. Therefore, the pIX phagemid 
vector pHEN9 was generated by replacing geneIII with geneIX within the phagemid vector 
pHEN4II (Zhang et al. 2001). The cloning strategy for the construction of pHEN9 is shown in 
Fig.III-10. 
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Fig.III-10: Cloning strategy for the construction of pHEN9 phagemid vector. GeneIII of 
pHEN4II phagemid vector (II.1.4.2.1) was replaced by geneIX in order to create pHEN9 
phagemid vector. Phage geneIX was amplified by PCR (II.2.1.2.1) using fd-tet (Zacher et al. 
1980) and primers p-5’-p9NotIa, p-5’-p9NotIb and p-3’-p9EcoRI (II.1.7.5). p-5’-p9NotIa/b: 
forward primers for the amplification of phage geneIX open reading frame and for insertion of 
a NotI-restriction site and a c-myc tag at the 5’-end of this sequence; p-3’-p9EcoRI: backward 
primer for the amplification of phage geneIX open reading frame and for insertion of an EcoRI-
restriction site at the 3’-end of this sequence. Amplified geneIX was cloned into NotI/EcoRI-
digested pHEN4II phagemid vector (Zhang et al. 2001). Sequencing analysis was done using 
primers p-5’-pHENx and p-3’-pHENx (II.1.7.5). 
 
III.2.1.2 Analysis of phagemid vector pHEN9 
In order to prove the functionality of the newly synthesized pIX-display system, the 
scFvCWPD2 cDNA encoding for the single chain antibody scFvCWPD2 (Peschen et al. 
2004) was cloned into the pHEN9 phagemid vector. ScFvCWPD2 specifically binds to a cell 
wall protein extract of fusarium (CWP antigen) and was chosen because a well-established 
phage ELISA set-up was available. The cloning strategy of pHEN9-CWP is shown in Fig.III-
11.  
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Fig.III-11: Cloning strategy for the construction of pHEN9-CWP phagemid vector. The 
DNA sequence encoding for the single chain antibody scFvCWPD2 (Peschen et al. 2004), 
which binds specifically to fusarium cell wall proteins, was cloned into pHEN9 phagemid vector 
(Fig.III-10). Gene scFvCWPD2 and upstream pelB-signal sequence were excised from pHEN-
CWPD2 (Peschen et al. 2004) using HindIII/NotI-restriction sites and cloned into HindIII/NotI-
digested phagemid vector pHEN9 (Fig.III-10). Sequencing analysis was done using primers p-
5’-pHENx and p-3’-pHENx (II.1.7.5). 
 
The binding capacity of the pHEN9-CWP phages (Fig.III-11) and the original pHEN-CWP 
phages (Peschen et al. 2004) to CWP antigen was determined by CWP phage ELISA 
(II.2.2.5.2). The results shown in Fig.III-12 allow the direct comparison of the pIII- and pIX-
display system.  
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Fig.III-12: CWP phage ELISA with pHEN9-CWP. In order to investigate the functional display 
of scFvCWPD2 as a pIX-fusion using pHEN9-CWP a CWP phage ELISA (II.2.2.5.2) was 
performed. Binding activity of pHEN9-CWP phages to CWP antigen was determined in 
comparison to pHEN-CWP phages, displaying scFvCWP as a fusion to the pIII coat protein. 
Serial dilutions of the phages (stock = 1012 phages/ml) were applied to a microtiter plate 
coated with CWP antigen and specific binding phages were detected using a 1:2,000 diluted 
HRP-conjugated mouse anti-M13 antibody. For detection ABTS (Roche) substrate was used 
and OD405nm was measured. Phages prepared by using pHENHi (II.1.4.2.2) phagemid vector 
were used to determine unspecific binding activity. The data were acquired in triplicate and the 
mean OD405nm was calculated and is shown above. 
 
The results confirm the data of Gao et al. (Gao et al. 1999; Gao et al. 2002a; Gao et al. 
2002b; Gao et al. 2003) and prove the integrity of the pIX-display system. However, pIX-
displayed scFvCWP fragments showed weaker binding activity to the CWP antigen than the 
same antibody fragment fused to pIII coat protein. Nevertheless, geneIX was chosen for the 
construction of the bispecific phagemid vector pHEN3+9 (Fig.III-14). 
 
III.2.2 Construction of bispecific phagemid vector pHEN3+9 
The bispecific phagemid vector pHEN3+9 was generated by inserting a second expression 
cassette encoding for geneIX into the pHENHi phagemid vector (Peschen et al. 2004) as 
described above. A SfiI/NotI-restriction site and the linker sequence 218 of phagemid vector 
pHEN9 (Fig.III-10) were replaced by a multi cloning site (MCS). The cloning strategy for the 
generation of pHEN9-Bi is shown in Fig.III-13. 
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Fig.III-13: Cloning strategy for the construction of intermediate pHEN9-Bi. p-5’-HindIII 
(II.1.7.6): forward primer for the amplification of amplicon A; p-3’-HEN39a and p-3’-HEN39b 
(II.1.7.6): backward primer for the amplification of amplicon A and for insertion of a 
XhoI/XbaI/EcoRI-restriction sites at the 3’-end of pelB leader sequence and for removement of 
the SfiI-restriction site; p-5’-HEN39a and p-5’-HEN39b (II.1.7.6): forward primer for the 
amplification of amplicon B and for insertion of a XhoI/XbaI/EcoRI/PstI/NcoI-restriction sites 
(MCS) at the 5’-end of the c-myc tag and for removement of the NotI-restriction site; p-3’-EcoRI 
(II.1.7.6): backward primer for the amplification of amplicon B. Amplicon A and B were 
assembled using SOE-PCR (II.2.1.2.2) and subsequently cloned into HindIII/EcoRI-digested 
phagemid vector pHEN9 (Fig.III-10). Sequencing analysis was done using primers p-5’-pHENx 
and p-3’-pHENx (II.1.7.5). 
The newly designed expression cassette of pHEN9-Bi was used as template for the 
generation of the bispecific phagemid vector pHEN3+9 and the cloning strategy is shown in 
Fig.III-14. 
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Fig.III-14: Cloning strategy for the construction of bispecific phagemid vector pHEN3+9. 
p-5’-HEN9Eco (II.1.7.7): forward primers for the amplification of geneIX expression cassette of 
intermediate pHEN9-Bi and for insertion of an EcoRI-restriction site at the 5’-end of this 
sequence; p-3’-HEN9Eco (II.1.7.7): backward primer for the amplification of geneIX 
expression cassette of intermediate pHEN9-Bi. Amplified geneIX expression cassette was 
cloned into EcoRI-digested pHENHi phagemid vector (II.1.4.2.2; Peschen et al. 2004). 
Sequencing analysis was done using primers p-5’-H39Seq (II.1.7.7) and p-3’-HENx (II.1.7.5). 
 
III.2.3 Analysis of bispecific phagemid vector pHEN3+9 
III.2.3.1 Construction and analysis of pHEN3CWP+9 
Firstly, the scFvCWPD2 DNA was cloned as fusion to geneIII into the bispecific phagemid 
vector pHEN3+9 (Fig.III-14), in order to confirm that the insertion of a second expression 
cassette (for geneIX-fusion) did not affect the functionality of the first one (for geneIII-fusion). 
The resulting pHEN3CWP+9 phages were analyzed by CWP phage ELISA (II.2.2.5.2). The 
cloning strategy of pHEN3WP+9 is shown in Fig.III-15. 
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Fig.III-15: Cloning strategy for the construction of pHEN3CWP+9 phagemid vector. 
Gene scFvCWPD2 encoding for the single chain antibody scFvCWPD2 (Peschen et al. 2004) 
was cloned into the bispecific phagemid vector pHEN3+9 (Fig.III-14). Gene scFvCWPD2 was 
excised from pHEN9-CWP (Fig.III-11) using the SfiI/NotI-restriction sites and cloned into 
SfiI/NotI-digested bispecific phagemid vector pHEN3+9 (Fig.III-14). Sequencing analysis was 
done using primers p-5’-biHEN3 and p-3’-biHEN3 (II.1.7.8). 
 
The binding efficiency of the pHEN3CWP+9 phages (Fig.III-15) to CWP antigen was 
determined by CWP phage ELISA (II.2.2.5.2) and compared to pHEN-CWP phages 
(Peschen et al. 2004), displaying the scFv as a fusion to geneIII but lacking the second 
expression cassette. The results are shown in Fig.III-16.  
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Fig.III-16: CWP phage ELISA with pHEN3CWP+9. In order to anaylze if the insertion of the 
second expression cassette for construction of the bispecific phagemid vector pHEN3+9 affect 
the functionality of the first one, scFvCWPD2 gene was cloned into the first cassette and the 
binding activity of the corresponding phages was checked by CWP phage ELISA (II.2.2.5.2). 
Binding activity of pHEN3CWP+9 phages to CWP antigen was determined in comparison to 
pHEN-CWP phages, lacking the second expression cassette. A serial dilution of the phages 
(stock = 1012 phages/ml) were applied to microtiter plates coated with CWP antigen and 
specific binding phages were detected using a 1:2000 diluted HRP-conjugated mouse anti-
M13 antibody. For detection ABTS substrate (Roche) was used and OD405nm was measured. 
pHENHi phages (II.1.4.2.2; Peschen et al. 2004) were used to determine unspecific binding 
activity. The data were acquired in triplicate and the mean OD405nm was calculated and is 
shown above. 
No significant difference in the binding activity of pHEN3CWP+9 and pHEN-CWP phages 
was observed. Both phagemid vectors allow functional display of the scFvCWPD2 antibody 
fragment as fusion to phage coat protein pIII. Thus, insertion of the second expression 
cassette (for geneIX-fusion) downstream of geneIII within the pHENHi phagemid vector does 
not affect the functionality of the scFv fused to geneIII.  
 
III.2.3.2 Construction and analysis of pHEN3CWP+9Strep 
The next step to reach the projects aim was the generation of a second binding moiety fused 
to pIX coat protein. Therefore, a protein or peptide motif had to be determined, suitable for 
immobilization on the biotinylated surface of the Protein Nanochip. Tetrameric streptavidin, 
the most commonly used biotin binding protein, cannot be used because phagemid vectors 
lead to monovalent display and the binding affinity of monomeric streptavidin is dramatically 
decreased in comparison to its tetrameric form. Recombinant monomeric avidin (Airenne et 
al. 1994; Airenne et al. 1999) might have been a suitable binding moiety but unfortunately the 
DNA sequence was not accessible and there was no time for repeating Airenne’s work. 
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Therefore, the Strep-tag® (IBA GmbH, Göttingen) was cloned as a fusion to geneIX within the 
bispecific phagemid pHEN3+9. The Strep-tag® is an eight amino acid streptavidin binding 
peptide and should allow the indirect immobilization of phages to the biotinylated chip 
surface via soluble tetrameric streptavidin as this consists of four binding domains. The 
Strep-tag® technology has been developed by IBA GmbH in Göttingen and provides a tool for 
expression, purification and detection of Strep-tag® fusion proteins. Recombinant streptavidin 
has been engineered by IBA GmbH and the resulting Strep-Tactin® possesses an optimized 
binding efficiency to Strep-tag® fusion proteins. Based on Strep-Tactin® IBA GmbH provides 
coated columns, cartridges, microtiter plates as well as magnetic beads for purification and 
detection of recombinant Strep-tag® proteins. This technology was adapted to filamentous 
bacteriophages in order to allow purification (II.2.2.4.1; Fig.III-32), detection by phage ELISA 
(II.2.2.5.3; Fig.III-30), and indirect immobilization on biotinylated surfaces (II.2.2.5.4; Fig.III-
31). The adjustment of this technology to filamentous bacteriophages is described in detail in 
III.3. The results discussed in III.3 indicate that the Strep-tag® is a suitable peptide motif for 
the side-directed immobilization of phages when displayed as a fusion to geneIX. For the 
cloning of the Strep-tag® DNA into the bispecific phagemid pHEN3CWP+9 (Fig.III-15) the 
intermediate pHEN3+9Strep phagemid vector was generated. The two step cloning strategy 
was necessary because the scFvCWP DNA possesses an internal EcoRI-restriction site and 
EcoRI had to be used for subsequent cloning of the Strep-tag®/geneIX PCR product. 
Therefore, the tag-PCR product was cloned into the “empty” bispecific phagemid vector 
pHEN3+9 (Fig.III-17) followed by integration of the scFvCWPD2 DNA, which was excised 
from the pHEN3CWP+9 phagemid vector and cloned into the intermediate pHEN3+9Strep 
using the SfiI/NotI-restriction sites (Fig.III-18). The cloning strategy of the intermediate 
pHEN3+9Strep is shown in Fig.III-17 and the construction of the final bispecific phagemid 
vector in Fig.III-18. 
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Fig.III-17: Cloning strategy for the construction of intermediate pHEN3+9Strep. p-5’-
HEN9Eco (II.1.7.7): forward primer for the amplification of amplicon A; p-3’-StrepIXa and p-
3’-StrepIXb (II.1.7.9): backward primer for the amplification of amplicon A and for insertion 
of the Strep-tag® sequence at the 3’-end of the pelB leader sequence; p-5’-StrepIX 
(II.1.7.9): forward primer for the amplification of amplicon B and for insertion of the Strep-
tag® sequence at the 5’-end of the c-myc tag; p-3’-HEN9Eco (II.1.7.7): backward primer for 
the amplification of amplicon B. Amplicon A and B were assembled using SOE-PCR 
(II.2.1.2.2) and subsequently cloned into EcoRI-digested bispecific phagemid vector 
pHEN3+9 (Fig.III-14); Strep: DNA sequence encoding for the Strep-tag® (IBA GmbH). 
Sequencing analysis was done using primers p-5’-H39Seq (II.1.7.7), p-3’biHEN9 (II.1.7.9) 
and p-3’-pHENx (II.1.7.5). 
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Fig.III-18: Cloning strategy for the construction of pHEN3CWP+9Strep phagemid vector. 
Gene scFvCWPD2 encoding for the single chain antibody scFvCWPD2 (Peschen et al. 2004), 
was cloned into the intermediate phagemid vector pHEN3+9Strep (Fig.III-17). Gene 
scFvCWPD2 was excised from pHEN3CWP+9 (Fig.III-15) using the SfiI/NotI-restriction sites 
and cloned into SfiI/NotI-digested phagemid vector pHEN3+9Strep (Fig.III-17). Strep: DNA 
sequence encoding for the Strep-tag® (IBA GmbH). Sequencing analysis was done using 
primers p-5’-biHEN3 and p-3’-biHEN3 (II.1.7.8) as well as p-5’-H39Seq (II.1.7.7) and p-3’-
biHEN9 (II.1.7.9). 
 
The functional display of the Strep-tag® on pIX coat protein of bispecific pHEN3CWP+9Strep 
phages was confirmed by Strep-Tactin® phage ELISA (II.2.2.5.3) in direct comparison to the 
pHEN9-Strep (Fig.III-19). An additional CWP phage ELISA (II.2.2.5.2) was performed to 
confirm these results, and exclude a negative effect on the scFvCWPD2/pIII fusion protein 
expression by insertion of the Strep-tag® into the second expression cassette. The results 
are shown in Fig.III-20.  
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Fig.III-19: Strep-Tactin® phage ELISA with pHEN3CWP+9Strep. In order to confirm the 
functional display of the Strep-tag® on pIX coat protein of bispecific pHEN3CWP+9Strep 
phages (Fig.III-18) a Strep-Tactin® phage ELISA (II.2.2.5.3) was performed. Binding activity of 
pHEN3CWP+9Strep phages to Strep-Tactin® coated microtiter plates (IBA GmbH) was 
determined in comparison to pHEN9-Strep (Fig.III-28) phages. A serial dilution of the phages 
(stock = 1014 phages/ml) were applied to the Strep-Tactin® coated microtiter plates and 
specific binding phages were detected using a 1:2,000 diluted HRP-conjugated mouse anti-
M13 antibody. For detection ABTS substrate (Roche) was used and OD405nm was measured. 
pHENHi phages (II.1.4.2.2) were used to determine unspecific binding activity. The data were 
acquired in triplicate and the mean OD405nm was calculated and is shown above. 
 
Fig.III-20: CWP phage ELISA with pHEN3CWP+9Strep. In order to verify the functional 
display of the scFvCWPD2 on pIII coat protein of bispecific pHEN3CWP+9Strep phages a 
CWP phage ELISA (II.2.2.5.2) was performed. Binding activity of pHEN3CWP+9 phages to 
CWP antigen was determined in comparison to pHEN-CWP phages. A serial dilution of the 
phages (stock = 1012 phages/ml) were applied to microtiter plates coated with CWP antigen 
and specific binding phages were detected using a 1:2,000 diluted HRP-conjugated mouse 
anti-M13 antibody. For detection ABTS substrate (Roche) was used and OD405nm was 
measured. pHENHi phages (II.1.4.2.2) were used to determine unspecific binding activity. 
The data were acquired in triplicate and the mean OD405nm was calculated and is shown 
above. 
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Insertion of the Strep-tag® into the second expression cassette of phagemid vector 
pHEN3CWP+9Strep did not alter the binding activity of the scFvCWPD2/pIII-fusion proteins 
encoded by the first expression cassette. In addition binding activity of pHEN3CWP+9Strep 
phages to Strep-Tactin® was shown proving the functionality of the second expression 
cassette. These results clearly demonstrated that the bispecific phagemid vector 
pHEN3CWP+9Strep allows the production of phages displaying either functional 
scFvCWPD2 antibody fragments on pIII coat protein or the Strep-tag® on pIX coat protein. 
The integrity of both expression cassettes of the pHEN3CWP+9Strep phagemid vector was 
proven. However, the simultaneous display of both proteins cannot be verified employing this 
set-up. 
 
III.2.3.3 Analysis of bispecific filamentous bacteriophages 
III.2.3.3.1 Analysis of bispecific phages by Phage ELISA 
Employing the phagemid system for the generation of bispecific phages requires the usage 
of a helperphage for the initiation of the assembly process. This leads to the competition of 
wild type pIII and pIX coat proteins encoded by the helperphage genome with the fusion 
proteins encoded on the bispecific phagemid vector for the assembly into the final phage 
particles. Thus, over 90% of rescued phages do not display the foreign proteins at all and in 
addition the display is monovalent (Marks et al. 1992; O’Connell et al. 2002). In conclusion 
less than 10% of the produced pHEN3CWP+9Strep phages display either the scFvCWPD2 
antibody fragment or the Strep-tag® on their surface and even less phages will display both 
foreign proteins and are therefore bispecific. The percentage of bispecific phages within the 
rescued phage population had to be investigated in order to prove the integrity of the 
phagemid vector pHEN3+9 as a suitable tool for the Protein Nanochip.  
Therefore, additional phage ELISA set ups were tested: 
I. Modified Strep-Tactin® phage ELISA (II.2.2.5.3) 
Strep-Tactin® binding phages were detected using a mouse anti-6xHis antibody (Qiagen; 
II.1.3) and an HRP-conjugated goat anti mouse antibody (II.1.3) instead of the HRP-
conjugated mouse anti-M13 antibody (II.1.3). The mouse anti-6xHis antibody was used in 
order to determine the display of 6xHis-tagged scFvCWPD2 antibody fragment on the 
surface of Strep-Tactin® binding phages. However, after applying the ABTS substrate, it was 
not possible to obtain specific signals measuring the OD405nm. Moreover, Strep-Tactin® Phage 
ELISA set ups using different anti-6xHis antibodies and different HRP-conjugated goat anti-
mouse antibodies or using directly HRP-conjugated anti 6xHis antibodies failed.  
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II. Modified CWP Phage ELISA (II.2.2.5.2) 
It was attempted to reveal CWP-binding phages by Strep-tag® specific antibodies from IBA 
GmbH (II.1.3) as well as from Qiagen but no binding could be detected. Finally, recombinant 
HRP-conjugated Strep-Tactin® (IBA GmbH) was used for detection of CWP-binding phages 
and the results obtained are shown in Fig.III-21.  
 
Fig.III-21: CWP phage ELISA with pHEN3CWP+9Strep for detection of bispecificity. In 
order to determine bispecific pHEN3CWP+9Strep phages a CWP phage ELISA (II.2.2.5.2) 
was performed using horseradish peroxidase (HRP) conjugated Strep-Tactin® (IBA GmbH) 
instead of anti-M13 antibody for detection of CWP antigen binding phages. Binding activity 
of pHEN3CWP+9Strep phages to CWP antigen was determined in comparison to pHEN-
CWP phages not displaying the Strep-tag®. Serial dilution of each phages (stock = 1014 
phages/ml) were applied to microtiter plates coated with CWP antigen and specific binding 
phages were detected using 1:2000 diluted HRP-conjugated Strep-Tactin® (IBA GmbH). 
For detection ABTS substrate (Roche Diagnostics) was applied and OD405nm was 
measured. pHENHi phages (II.1.4.2.2) were used to determine unspecific binding activity. 
The data were acquired in triplicate and the mean OD405nm was calculated and is shown 
above. 
 
The usage of recombinant HRP-conjugated Strep-Tactin® caused high background signals 
within this modified CWP phage ELISA. The obvious reason for this background signal was 
the binding activity of Strep-Tactin® to fusarium biotin that is a natural component of the CWP 
extract which was coated on the microtiter plates. Despite this high background signal, a 
positive tendency was observed for the concentrated pHEN3CWP+9Strep phages in 
comparison to the control phages. Therefore, the ELISA was repeated by adding soluble 
unconjugated streptavidin (Roche Diagnostics) to the blocking solution in order to saturate 
the coated fusarium biotin and thus reduce the unspecific background signal. 
The results obtained with this ELISA set up are shown in Fig.III-22. 
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Fig.III-22: CWP phage ELISA with pHEN3CWP+9Strep for detection of bispecificity. In 
order to determine bispecific pHEN3CWP+9Strep phages a CWP phage ELISA (II.2.2.5.2) 
was performed using horseradish peroxidase (HRP) conjugated Strep-Tactin® (IBA GmbH) 
for detection of CWP antigen binding phages. For decrease of unspecific binding of HRP-
conjugated Strep-Tactin®, soluble recombinant streptavidin (Roche Diagnostics) were 
added 1:5,000 diluted to the blocking solution. Binding activity of pHEN3CWP+9Strep 
phages to CWP antigen was determined in comparison to pHEN-CWP phages not 
displaying the Strep-tag®. A serial dilution of the phages (stock = 1014 phages/ml) were 
applied to microtiter plates coated with CWP antigen and specific binding phages were 
detected using a 1:2,000 diluted HRP-conjugated Strep-Tactin® (IBA GmbH). For detection 
ABTS substrate (Roche diagnostics) was used and OD405nm was measured. pHENHi 
phages (II.1.4.2.2; Peschen et al. 2004) were used to determine unspecific binding activity. 
The data were acquired in triplicate and the mean OD405nm was calculated and is shown 
above. 
 
The corresponding results obtained (Fig.III-22) confirmed the assumption that fusarium biotin 
caused the high background signal because the unspecific signal was significantly 
decreased. Again the positive tendency of pHEN3CWP+9Strep phages was visible and even 
became stronger, giving a first hind for “real” bispecific phages. Nevertheless, the extinction 
of the pHEN3CWP+9Strep phages did not provide significant positive signals in comparison 
to the control phages. Further supporting these results another strategy for detection of 
bispecific phages was developed 
III. CWP Phage ELISA using Strep-Tactin® purified pHEN3CWP+9Strep phages  
In order to verify this positive tendency another strategy for detection of bispecific phages 
was developed. As described above, only a small percentage of the prepared 
pHEN3CWP+9Strep phages are theoretically bispecific indicating the need for an enrichment 
of these phages before applying them to the microtiter plates and thus perhaps allow 
reaching the detection limit. Therefore, a novel purification method was established for the 
enrichment of bispecific phages. As described in II.2.2.4.1 and shown in Fig.III-32 Strep-
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Tactin® cartridges (IBA GmbH) provide a suitable tool for the purification of Strep-tag® 
displaying phages. This technology was used to enrich bispecific phages by purifying the 
Strep-tag® displaying ones and removing the phages only displaying the single chain Fv 
antibody or none of the foreign proteins. Finally, binding activity to the CWP antigen of these 
Strep-Tactin® affinity purified pHEN3CWP+9Strep phages was verified by CWP phage 
ELISA (Fig.III-23). 
 
Fig.III-23: CWP phage ELISA with Strep-Tactin® purified pHEN3CWP+9Strep for 
detection of bispecificity. In order to check the bispecificity of the pHEN3CWP+9Strep 
phages a combinatorial assay was created. Freshly prepared phages (Maxi Phage 
Preparation; II.2.2.2) were purified (II.2.2.4.1) using Strep-Tactin® cartridges (IBA GmbH) 
and subsequently a CWP phage ELISA (II.2.2.5.2) was performed using the unpurified and 
the purified Strep-tag® displaying phages. Binding activity of purified and unpurified 
pHEN3CWP+9Strep phages to CWP antigen was determined in comparison to purified and 
unpurified pHEN-CWP (Peschen et al. 2004) and pHEN-Strep (Fig.III-29) phages. A serial 
dilution of the phages (stock = 1012 phages/ml) were applied to microtiter plates coated with 
CWP antigen and specific binding phages were detected using a 1:2000 diluted HRP-
conjugated mouse anti-M13 antibody. For detection ABTS (Roche) substrate was used and 
OD405nm was measured. pHENHi phages (II.1.4.2.2) were used to determine unspecific 
binding activity. The data were acquired in triplicate and the mean OD405nm was calculated 
and is shown above. 
 
Strep-Tactin® affinity purified pHEN3CWP+9Strep phages showed significant binding activity 
to the CWP antigen compared to Strep-Tactin® purified pHEN-Strep (Fig.III-29) phages not 
displaying the scFvCWPD2 antibody fragment. Thus the presence of “true” bispecific phages 
displaying the single chain antibody fragment and the Strep-tag® could be confirmed. In 
addition it was clearly demonstrated that only Strep-tag® displaying phages were specifically 
purified using Strep-Tactin® cartridges, because unpurified pHEN-CWP phages lead to high 
O
D
 4
05
nm
 
phage dilution 
1:2 1:8 1:321:128 1:512 1:2048 
stock = 1012 phages/ml
0 
0,5 
1 
1,5
2 
2,5 
3 
3,5 
4 
4,5 
pHEN3CWP+9Strep
pHEN3CWP+9Strep pur.
pHEN-CWP 
pHEN-CWP pur.
pHEN-Strep 
pHEN-Strep pur.
pHENHi 
III Results and Discussion 77
extinction signals whereas no binding activity to CWP antigen could be observed with Strep-
Tactin® purified pHEN-CWP phages.  
This combinatorial assay provides the first evidence for the integrity of the bispecific 
phagemid vector pHEN3+9 to be a suitable tool for the envisaged application, which is the 
immobilization of protein libraries on the surface of the Protein Nanochip. 
III.2.3.3.2 Analysis of bispecific phages by immunogold assay and EM 
The phage ELISA results were confirmed by electron microscopical analysis performing an 
immunogold assay. According to the phage ELISA analysis, several set ups of the 
immunogold assay had to be investigated to determine the optimal set up. Finally, 
pHEN3CWP+9Strep phages (Maxi prep; II.2.2.2) were affinity purified using Strep-Tactin® 
cartridges (II.2.2.4.1) and immobilized on Ni-grids (II.2.2.6.1) for subsequent immunological 
detection of the 6xHis-tagged scFvCWPD2 fragment and the Strep-tag® displayed on the 
phage surface. Parallel detection of both foreign proteins on the surface of the immobilized 
phages was tried to be achieved by incubation with two different first antibodies and two 
different secondary gold-conjugated antibodies (II.2.2.6.2; first set up). A Strep-tag® specific 
mouse antibody (II.1.3) and a polyclonal rabbit anti-6xHis antibody (II.1.3) were chosen for 
the first incubation step and for visualization of these first antibodies, a 15nm gold-
conjugated goat anti-mouse antibody and a 10nm gold-conjugated goat anti-rabbit antibody 
(II.1.3) were used. The results of the subsequent electron microscopical analysis of these 
samples are shown in Fig.III-24 and Fig.III-25. 
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Fig.III-24: Immunogold based analysis of bispecific pHEN3CWP+9Strep phages: 
pHEN3CWP+9Strep phages (Fig.III-18; II.2.2.2) were purified via Strep-Tactin® cartridge 
(II.2.2.4.1), immobilized on Ni-grids (II.2.2.6.1) for subsequent immunological detection with 
gold-labelled antibodies (II.2.2.6.2, first set up) and analyzed by electron microscopy 
(II.2.2.6). Detection and visualization of the His6-tagged scFvCWPD2 and the Strep-tag® 
on the surface of the pHEN3CWP+9Strep phages was realized using two different primary 
antibodies. A polyclonal rabbit anti-6xHis antibody (II.1.3) was used for detection of the 
6xHis-tagged scFvCWPD2 displayed on phage pIII coat protein and a monoclonal Strep-
tag® specific mouse antibody (II.1.3) was used for detection of the Strep-tag® displayed on 
phage pIX coat protein. The two primary antibodies were detected by using two different 
secondary, gold-labelled antibodies. A 10nm gold-conjugated goat anti-rabbit IgG antibody 
and 15nm gold-conjugated goat anti-mouse IgG antibody (II.1.3) were used, allowing the 
specific detection of the His6-tagged scFvCWPD2 and the Strep-tag® on the phage surface 
in parallel. The following magnifications were used in electron microscopy: A: 130,000x; B: 
80,000x; C: 100,000x. 
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Fig.III-25: Immunogold based analysis of bispecific pHEN3CWP+9Strep phages: 
pHEN3CWP+9Strep phages (Fig.III-18; II.2.2.2) were purified via Strep-Tactin® cartridge 
(II.2.2.4.1), immobilized on Ni-grids (II.2.2.6.1) for subsequent immunological detection with 
gold-labelled antibodies (II.2.2.6.2, first set up) and analyzed by electron microscopy 
(II.2.2.6). Detection and visualization of the His6-tagged scFvCWPD2 and the Strep-tag® 
on the surface of the pHEN3CWP+9Strep phages was realized using two different primary 
antibodies. A polyclonal rabbit anti-6xHis antibody (II.1.3) was used for detection of the 
6xHis-tagged scFvCWPD2 displayed on phage pIII coat protein and a monoclonal Strep-
tag® specific mouse antibody (II.1.3) was used for detection of the Strep-tag® displayed on 
phage pIX coat protein. The two primary antibodies were detected by using two different 
secondary, gold-labelled antibodies. A 10nm gold-conjugated goat anti-rabbit IgG antibody 
and 15nm gold-conjugated goat anti-mouse IgG antibody (II.1.3) were used, allowing the 
specific detection of the His6-tagged scFvCWPD2 and the Strep-tag® on the phage surface 
in parallel. The following magnifications were used in electron microscopy: A: 100,000x; B: 
80,000x; C: 130,000x.  
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The electron microscopical pictures presented in Fig.III-24 and Fig.III-25 show a selection of 
specifically gold-decorated pHEN3CWP+9Strep phages. The results of this electron 
microscopical analysis clearly demonstrate the functional display of either the scFvCWPD2 
antibody fragment or the Strep-tag®. The six phages depicted in Fig.III-24 and Fig.III-25 were 
either decorated with 10nm or with 15nm gold particles and in addition to these selected 
ones, several equally labelled phages have been determined. The immunological gold-
labelling of all phages was focussed at the display area of the recombinant proteins and only 
observed on their tip and none of the analyzed phages show gold-labelling on their middle 
portion. These observations confirm the model of the structure of filamentous bacteriophages 
shown in Fig.I-1 and prove that pIII and pIX coat proteins are incorporated at the tip of each 
phage.  
In order to facilitate the separation between 10nm and 15nm gold particles, phages were 
shown separately. Fig.III-24 shows three different pHEN3CWP+9Strep phages decorated 
with 10nm gold-conjugated antibodies at their tip, proving the functional display of the 6xHis-
tagged scFvCWPD2 antibody fragment on pIII coat protein. To facilitate the distinction 
between 10nm and 15nm gold particles, picture C of Fig.III-24 shows a decorated phage in 
close proximity to unspecifically adsorbed 15nm gold-conjugated antibodies, clearly 
demonstrating that the bacteriophage is decorated with 10nm gold particles. All phages 
shown in Fig.III-25 were decorated with 15nm gold-conjugated antibodies, proving the 
functional display of the Strep-tag® on pIX coat protein. Again one picture (picture C) shows a 
decorated phage in close proximity to unspecifically adsorbed gold-conjugated antibodies but 
this time the unspecific adsorpted antibodies are conjugated with 10nm gold particles and the 
bacteriophages shown are decorated with 15nm gold-conjugated antibodies.  
Interestingly, more 10nm gold particles per phage tip could be observed in comparison to the 
15nm gold particles. Whereas up to seven 10nm gold particles were observed to bind to one 
phage tip, just three copies of 15nm gold particles were maximum found to bind to one tip. A 
reason for this phenomenon might be the higher flexibility of the pIII-fusion proteins and thus 
a better accessibility of the 6xHis-tagged scFvCWPD2 due to the length of the pIII coat 
protein in comparison to pIX. Phage pIII is a 42.5kD protein and pIX is a 3.6kD protein. An 
additional reason might be a low affinity of the Strep-tag® specific antibody (IBA GmbH, 
Göttingen) that was already observed by the results of the modified CWP Phage ELISA set 
up. The fact, that only one in a hundred phages was specifically decorated with 15nm gold 
particles additionally confirms this hypothesis. Theoretically all phages should have been 
decorated at least with one 15nm gold-conjugated antibody because the phages were affinity 
purified via Strep-Tactin® cartridges and thus should all display the Strep-tag® on their 
surface. These observations leaded to the development of another detection set up for this 
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immunogold assay, which finally allows the visualization of a “real” bispecific filamentous 
bacteriophage. Again Strep-Tactin® (IBA GmbH) was chosen for the detection of the Strep-
tag® displaying phages but for the immunogold assay a HRP-conjugated version was used. 
These HRP-conjugated Strep-Tactin® molecules were visualized by applying a 10nm gold-
conjugated goat anti-HRP antibody (II.1.3). For detection of the 6xHis-tagged scFvCWPD2 
antibody fragments on the other side of the phages a monoclonal mouse anti-penta-His 
antibody (II.1.3) and a 15nm gold-conjugated goat anti-mouse antibody (II.1.3) were utilized. 
In order to avoid unspecific binding of the HRP-conjugated Strep-Tactin® to hydroxybiotin 
that had to be used for competitive elution of Strep-tag® phages from the Strep-Tactin® 
cartridges, an additional purification method was developed for the enrichment of bispecific 
phage particles. Ni-NTA cartridges (IBA GmbH) were used instead of the Strep-Tactin® ones 
and the protocols (II.2.2.4.2) were adapted for the purification of 6xHis-tag displaying phages 
and thus for enrichment of bispecific phages. These Ni-NTA purified pHEN3CWP+9Strep 
bacteriophages were immobilized on Ni-grids and analyzed using the described second set 
up of the immunogold assay (II.2.2.6.2; second set up) and electron microscopy. The results 
of the electron microscopical analysis are shown in Fig.III-26. 
 
Fig.III-26: Immunogold based analysis of bispecific pHEN3CWP+9Strep phages: 
pHEN3CWP+9Strep phages (Fig.III-18; II.2.2.2) were purified via Ni-NTA cartridge 
(II.2.2.4.2), immobilized on Ni-grids (II.2.2.6.1) for subsequent immunological detection with 
gold-labelled antibodies (II.2.2.6.2) and analyzed by electron microscopy (II.2.2.6). 
Detection and visualization of the 6xHis-tagged scFvCWPD2 and the Strep-tag® on the 
surface of the pHEN3CWP+9Strep phages was realized using two different primary binding 
proteins. A monoclonal mouse anti-penta-His antibody (II.1.3) was used for detection of the 
6xHis-tagged scFvCWPD2 displayed on phage pIII coat protein and horseradish 
peroxidase (HRP) conjugated Strep-Tactin® (IBA GmbH) was used for detection of the 
Strep-tag® displayed on phage pIX coat protein. The two primary binding molecules were 
detected by using two different secondary, gold-labelled antibodies. A 15nm gold-
conjugated goat anti-mouse IgG antibody (II.1.3) and a 10nm gold-conjugated goat anti-
HRP antibody (II.1.3) were used, allowing the specific detection of the 6xHis-tagged 
scFvCWPD2 and the Strep-tag® on the phage surface in parallel. Magnification of 
130,000x. 
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The electron micrograph presented in Fig.III-26 shows a bispecific pHEN3CWP+9Strep 
phage decorated with 10nm and with 15nm gold-conjugated antibodies. This picture clearly 
demonstrates bispecificity because on the left side 10nm gold-conjugated antibodies 
visualized the Strep-tag® fused to geneIX and on the right side 15nm gold-conjugated 
antibodies visualized the scFvCWPD2 fused to geneIII.  
These results prove the integrity of the bispecific phagemid vector pHEN3+9 (Fig.III-14) as a 
suitable tool for the realization of the Protein Nanochip. This phagemid vector allows the 
side-directed immobilization of protein libraries by displaying a suitable peptide motif (e.g. 
Strep-tag®) on the pIX coat protein and simultaneously displaying functional library proteins 
(e.g. scFv antibody fragments) fused to pIII coat protein at the opposite side of the 
filamentous bacteriophages. These results fulfilled the main milestones of the research 
project. 
With the establishment of the bispecific phagemid vector pHEN3CWP+9Strep and the 
proven generation of bispecific phages simultaneously displaying a functional scFv antibody 
on pIII and the Strep-tag® on the opposite side on pIX, immobilization of all kind of protein 
libraries on biotinylated or Strep-Tactin® coated surfaces becomes feasible. The functional 
display of the scFv antibody on the surface of these bispecific filamentous bacteriophages 
indicates that all other classes of proteins, as described by Smith and Petrenko (1997), could 
also be functionally displayed using the bispecific phagemid vector pHEN3+9. In conclusion, 
the immobilization of all kind of protein libraries, like genomic libraries (Jacobsson et al. 
1995), peptide libraries (Cwirla et al. 1990), different kinds of antibody libraries (Hoogenboom 
et al. 1991; Griffiths 1993; Winter et al. 1994), cDNA libraries (Crameri et al.1994; Crameri 
and Blaser 1996) and even full-length cDNA libraries using the Fos/Jun-system (Crameri and 
Suter, 1993; Palzkill et al. 1998) became possible and might be adapted to automated 
screening systems as e.g. the envisaged Protein Nanochip (Fig.I-9). 
Based on currently available literature these data confirm for first time that a bispecific 
filamentous bacteriophage was generated simultaneously displaying two different foreign 
proteins on its pIII and pIX coat protein. However, in August 2004 Chen et al. also published 
data describing a bispecific filamentous bacteriophage displaying an alpha integrin-targeting 
motif as a fusion to the pIII coat protein and a streptavidin binding peptide fused to the major 
pVIII coat protein (Chen et al. 2004). They did not use a phagemid vector for the construction 
of this bispecific vector system but a hybrid phage vector (Perham et al. 1995) or type-88 
phage vector (Zhong et al. 1994; Roberts et al. 1996; Bonnycastle et al. 1996), which had 
been used previously for displaying peptides longer than eight amino acids on the major coat 
protein pVIII. All these phage vectors are derivatives of the f88-4 phage vector (Zhong et al. 
1994) bearing two copies of geneVIII, encoding two different types of pVIII proteins, the 
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original wild type pVIII protein and a pVIII-fusion protein encoded by an additional 
recombinant geneVIII expression cassette inserted into the intergenic region of the phage 
vector. The resulting hybrid phages are mosaic and their coat is comprised both of wild type 
pVIII proteins and recombinant pVIII-fusion proteins. This provided pVIII fusion with larger 
foreign peptide sequences (up to 20mers) to be displayed on the phage surface, even 
though the fusion protein itself cannot support phage assembly. Although only 1% of the 
incorporated pVIII proteins are recombinant pVIII-fusion products it was possible to achieve a 
multivalent peptide display on the middle portion of the phage. Chen et al. combined a 
derivative of this f88-4 vector with a derivative of the fd-tet phage vector (Zacher et al. 1980) 
possessing a cloning site between geneIII signal sequence and geneIII in order to generate a 
kind of bispecific phage vector, which they call chimeric phage vector (Chen et al. 2004). 
Next to their specific therapeutic application, it should be possible to generate phages 
multivalently displaying library proteins on pIII coat protein at the tip and in parallel displaying 
peptides (up to 20mers) on 1% of the major coat protein pVIII on the middle portion of the 
phage. This kind of phages are not suitable for screening protein libraries via standard phage 
display, because the multivalent pIII-display leads to highly decreased infectivity of the 
phages and thus complicates the panning procedure. In addition, this chimeric phage vector 
cannot be used for the Protein Nanochip set up, although circumventing the panning 
procedure because the second specificity can only be displayed on the major coat protein 
pVIII and thus will not allow the side-directed immobilization of protein libraries.  
In addition, Chen’s results confirm the phagemid vector based strategy for the generation of 
bispecific filamentous bacteriophages allowing simultaneously display of two different 
proteins on pIII and pIX coat protein. The application for the set up described by Chen’s 
publication (Chen et al. 2004) shows an approach for finding novel carriers, which are 
targeting tumor cells and thus allow the specific delivery of therapeutics proteins. This 
interesting research project was supported by grants from the National Institutes of Health, 
the National Cancer Institute and the Department of Defence and some of the renowned 
scientists in the field of phage display worked on this project and George P. Smith the 
inventor of the original phage display technology was scientific adviser. Even these brilliant 
scientists did not provide a novel phage vector that is modified within the encoding regions of 
the phage genome, indicating that indeed it is very challenging to modify for example the 
original geneVI or geneIX within the phage genome and thus confirm the phagemid vector 
based strategy for the generation of bispecific phages allowing the display of two different 
foreign protein on pIII and pIX coat protein. Due to the project objective it was essential to 
combine exactly this pIII- and pIX-display system in order to allow the side-directed 
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immobilization and therefore it is the pHEN3+9 phagemid vector making the realization of the 
Protein Nanochip possible at all. 
III.3 Immobilization of phages using Strep-tag® 
technology 
III.3.1 Adjustment of the Strep-tag® technology to phages 
Side-directed immobilization of phage libraries on the surface of the Protein Nanochip (Fig.I-
9) was one research objective of this doctoral thesis. Due to the fact that the surface of the 
Protein Nanochip is biotinylated, determined by the technical research partner, a protein or 
peptide had to be found possessing specific binding activity to biotin when displayed on 
filamentous bacteriophage. Commonly used biotin-binding proteins are avidin or streptavidin, 
both tetrameric molecules with four biotin-binding domains per molecule. Native streptavidin 
is a prokaryotically expressed protein and therefore the better display motif for the envisaged 
application in comparison to the eukaryotically expressed avidin. But for functional display of 
the streptavidin molecule on the surface of filamentous bacteriophage a multivalent display of 
at least four streptavidin monomers is necessary to form a functional tetrameric streptavidin 
molecule. Unfortunately, it was not possible to achieve this multivalent display on pIX coat 
protein within the time of this thesis. A phagemid vector system had to be used for the 
generation of bispecific filamentous bacteriophages and the immobilization of protein libraries 
on the surface of the Protein Nanochip. Therefore, a monomeric biotin-binding protein or 
peptide had to be found suitable for functional display on the phage coat using this phagemid 
vector system. Firstly, recombinant monomeric avidin (Airenne et al. 1994; Airenne et al. 
1999) was thought to be an appropriate protein because this engineered avidin is functionally 
expressed in prokaryotes and shows good biotin-binding capabilities even in the monomeric 
form (Laitinen et al. 2003). Unfortunately, it was not possible to get access to the 
corresponding DNA sequence and due to a lack of time Airenne’s work was not repeated. 
Thus, the so called Strep-tag® (IBA GmbH) was chosen for the side-directed immobilization 
of bispecific phages on the biotinylated surface of the Protein Nanochip. The Strep-tag® is an 
eight amino acid peptide binding specifically to streptavidin or its engineered form Strep-
Tactin® and had been chosen as a suitable peptide motif for indirect immobilization of the 
corresponding phages to the chip surface. Strep-tag® displaying phages should be able to 
bind soluble tetrameric Strep-Tactin®, which in parallel is able to bind biotinylated surfaces by 
using one of its other three biotin binding domains. The Strep-tag® technology has been 
developed by IBA GmbH in Göttingen and provides a tool for expression, purification and 
detection of Strep-tag® fusion proteins. Recombinant streptavidin has been engineered by 
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IBA GmbH and the resulting Strep-Tactin® possesses an optimized binding capability to 
Strep-tag® fusion proteins. Based on Strep-Tactin® the IBA GmbH provides coated columns, 
cartridges, microtiter plates as well as magnetic beads for purification and detection of 
recombinant Strep-tag® proteins.  
The DNA and amino acid sequence of the Strep-tag® is shown in Fig.III-27.   
 
 
 
 
Fig.III-27: DNA and amino acid sequence of the Strep-tag® (IBA GmbH, Göttingen): 
The DNA sequence of the eight amino acid Strep-tag® is shown in the codon view. Below 
the DNA sequence the corresponding amino acid sequence of the Strep-tag® is shown. 
 
III.3.1.1 Generation of Strep-tag® phagemid vectors 
This Strep-tag® technology was adapted to the phagemid vector system in order to allow the 
side-directed immobilization of the phages to biotinylated surfaces. Therefore, the Strep-tag® 
DNA sequence was cloned into the phagemid vector pHENHi (Peschen et al. 2004) as a 
fusion to geneIII and into pHEN9 (Fig.III-10) as a fusion to geneIX. Subsequently, the 
streptavidin- and Strep-Tactin®-binding efficiency of the resulting phages was evaluated. The 
cloning strategies for the construction of the phagemid vectors pHEN-Strep and pHEN9-
Strep are shown in Fig.III-28 and Fig.III-29. These two cloning strategies were developed to 
determine differences in the binding properties of the Strep-tag® when being displayed either 
on pIII- or pIX coat protein. 
 
 
5’- TGG AGC CAC CCG CAG TTC GAA AAA -3’ 
         NH2 -  Trp - Ser  - His -  Pro - Gln - Phe - Glu - Lys  - COOH 
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Fig.III-28: Cloning strategy for the construction of phagemid vector pHEN9-Strep. p-
5’-HindIII (II.1.7.6): forward primers for the amplification of pelB signal sequence using 
phagemid vector pHEN9 (Fig.III-10) as template; p-3’-StrepI and p-3’-StrepII (II.1.7.10): 
backward primers for the amplification of pelB signal sequence and for insertion of the 
Strep-tag® (Strep) DNA sequence and a NotI-restriction site to the 3’-end of pelB signal 
sequence. Amplified pelB-Strep-tag® sequence was cloned into HindIII/NotI-digested 
phagemid vector pHEN9 (Fig.III-10). For sequencing primers refer to Fig.III-29. 
 
Fig.III-29: Cloning strategy for the construction of phagemid vector pHEN-Strep. C-
myc tag, 6xHis tag and geneIII were cloned into the phagemid vector pHEN9-Strep (Fig.III-
28). C-myc tag, 6xHis tag and geneIII were excised from pHENHi (II.1.4.2.2) using the 
NotI/EcoRI-restriction sites and cloned into NotI/EcoRI-digested phagemid vector pHEN9-
Strep (Fig.III-28). Sequencing analysis of pHEN9-Strep (Fig.III-28) and pHEN-Strep was 
done using primers p-5’HENSeq (II.1.7.10) and p-3’-pHENx.  
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III.3.1.2 Analysis of Strep-tag® displaying phages 
Functional display of the Strep-tag® on pIII- and pIX coat protein was analyzed by 
Streptavidin and Strep-Tactin® Phage ELISA (II.2.2.5.3) 
 
Fig.III-30: Streptavidin and Strep-Tactin® phage ELISA with pHEN-Strep and pHEN9-
Strep phages. In order to check the functional display of the Strep-tag® on pIII and pIX 
phage coat protein a Streptavidin (A) and a Strep-Tactin® (B) phage ELISA (II.2.2.5.3) was 
performed using pHEN-Strep (Fig.III-29) and pHEN9-Strep (Fig.III-28) phages. Binding 
activity of these phages to Streptavidin (Roche Diagnostics) and Strep-Tactin® (IBA GmbH) 
coated microtiter plates was determined. A serial dilution of both phages (stock = 1012 
phages/ml) were applied to the coated microtiter plates and specific binding phages were 
detected using a 1:2,000 diluted HRP-conjugated mouse anti-M13 antibody. For detection 
ABTS substrate (Roche) was used and OD405nm was measured. pHENHi phages 
(II.1.4.2.2) were used to determine unspecific binding activity. The data were acquired in 
triplicate and the mean OD405nm was calculated and is shown above. 
 
Surprisingly, the binding of the phages to streptavidin and Strep-Tactin® was only sustained 
when the Strep-Tag® was fused to the pIII phage coat protein. The same Strep-Tag® 
displayed on pIX phage coat protein looses the binding capability to recombinant 
streptavidin, whereas the Strep-Tactin® binding activity is not affected. Therefore, Strep-
Tactin® coated surfaces have to be employed to achieve side-directed immobilization of 
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bispecific phages on biochips or other matrices. However the projects aim was the 
immobilization on biotinylated surfaces and therefore the indirect binding activity of the 
pHEN9-Strep phages to biotin via soluble Streptavidin and Strep-Tactin® was determined. 
The results of this Biotin Phage ELISA (II.2.2.5.4.) are shown in Fig.III-31. 
 
Fig.III-31: Biotin phage ELISA with pHEN9-Strep. In order to check indirect binding 
activity of pHEN9-Strep (Fig.III-28) phages to biotinylated surfaces, a Biotin phage ELISA 
(II.2.2.5.4) was performed. Indirect binding activity of the Strep-tag® displaying phages to 
biotinylated microtiter plates (Pierce/Perbio; Bonn) was determined using soluble 
Streptavidin (Roche Diagnostics) and Strep-Tactin® (IBA GmbH) as a linker molecule. 
Soluble, unconjugated Streptavidin (A) or Strep-Tactin® (B) was applied to the biotinylated 
microtiter plate and binding activity of the pHEN9-Strep phages to bound Streptavidin or 
Strep-Tactin® was determined. A serial dilution of the phages (stock = 1012 phages/ml) 
were applied to the microtiter plates and specific binding phages were detected using a 
1:2,000 diluted HRP-conjugated mouse anti-M13 antibody. For detection ABTS substrate 
(Roche) was used and OD405nm was measured. pHENHi phages (II.1.4.2.2) were used to 
determine unspecific binding activity. The data were acquired in triplicate and the mean 
OD405nm was calculated and is shown above. 
 
Side-directed immobilization to biotinylated surfaces of phages displaying the Strep-tag® on 
pIX coat protein was possible using soluble Strep-Tactin® (IBA GmbH) as a linker molecule. 
Again, no binding activity to recombinant streptavidin (Roche) was be observed using 
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phages displaying the Strep-tag® on pIX. Perhaps, again it’s the higher flexibility of the longer 
pIII coat protein that facilitates binding of the displayed Strep-tag® also to its weaker binding 
partner streptavidin and not only to Strep-Tactin®. However, it could be clearly demonstrated 
that the Strep-tag® provides the tool for side-directed immobilization of bispecific filamentous 
bacteriophages. Considering these results and the functional display of the Strep-tag® on pIX 
coat protein of pHEN3CWP+9Strep phages (Fig.III-26), an immobilization of protein libraries 
on the surface of the Protein Nanochip becomes feasible. Unfortunately, it was not possible 
to prove this hypothesis because no prototype of the Protein Nanochip is available yet. 
III.3.2 Purification of phages using Strep-tag® technology 
In addition to the immobilization assays it was considered to use the Strep-tag®/Strep-Tactin® 
technology for purification and consequently for the enrichment of bispecific 
pHEN3CWP+9Strep phages as already mentioned in III.2. Therefore, a suitable purification 
protocol was established based on the Strep-Tactin® tools provided by IBA GmbH: 
• Strep-Tactin Sepharose® cartridge  
• Strep-Tactin Superflow® cartridge  
• Strep-Tactin MacroPrep® cartridge 
The established protocol for purification of Strep-Tactin® phage particles and enrichment of 
bispecific pHEN3CWP+9Strep phages is described in II.2.2.4.1. The successful enrichment 
was evaluated by Strep-Tactin® phage ELISA (II.2.2.5.3). Purified phages were dialyzed 
before being applied to the Strep-Tactin® coated microtiter plates. Elution of Strep-tag® 
phages from the Strep-Tactin® cartridges was achieved by competitive elution with 
hydroxybiotin and this component had to be removed before ELISA analysis because 
otherwise no binding activity of Strep-tag® phages could be determined.  The results of this 
assay are shown in Fig.III-32.  
The Strep-Tactin MacroPrep® cartridge clogged and thus no ELISA results are shown in 
Fig.III-32. pHEN-Strep phages (Fig.III-29) purified by Strep-Tactin Sepharose® or Strep-
Tactin Superflow® cartridges were applied to Strep-Tactin® coated microtiter plate in 
comparison to unpurified pHEN-Strep phages using stock solutions with the same phage 
concentration. The results shown in Fig.III-32 clearly demonstrate the successful enrichment 
of Strep-tag® displaying phages because 1:128 diluted purified phages show the same 
OD405nm as 1:8 diluted unpurified phages. Therefore, sixteen-fold enrichment was achieved 
by using either a Strep-Tactin Sepharose® or a Strep-Tactin Superflow® cartridge. Finally, the 
Superflow cartridges (II.2.2.4.1) were used for purification of Strep-tag® displaying phages 
because the flow rate was higher than with the Sepharose cartridge. In conclusion, the Strep-
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tag®/Strep-Tactin® technology provides a very useful tool for the purification and enrichment 
as well as side-directed immobilization of Strep-tag® displaying phages. 
 
Fig.III-32: Strep-Tactin® Phage ELISA with Strep-Tactin® cartridge purified pHEN-
Strep phages. Freshly prepared (Maxi prep; II.2.2.2) pHEN-Strep phages (Fig.III-29) were 
purified using Strep-Tactin® cartridges (IBA GmbH) as described in II.2.2.4.1. Three 
different Strep-Tactin® cartridges (Cartridge Evaluation Set; IBA GmbH) were tested for the 
most suitable matrix. Purification was done using a Sepharose, a Superflow and a 
MacroPrep cartridge.  After elution, the purified pHEN-Strep phages were dialysed to 
remove remaining hydroxybiotin and the binding activity of unpurified and purified phages 
to Strep-Tactin® was determined by Strep-Tactin® Phage ELISA (II.2.2.5.3). A serial dilution 
of the purified and unpurified phages (stock = 1012 phages/ml) were applied to Strep-
Tactin® coated microtiter plates and specific binding phages were detected using a 1:2,000 
diluted HRP-conjugated mouse anti-M13 antibody. For detection ABTS substrate (Roche) 
was used and OD405nm was measured. MacroPrep results are not shown because cartridge 
clogged and thus it wasn’t possible to elute any phages. 
 
Based on the Strep-Tactin® purification protocol (II.2.2.4.1) a second purification procedure 
was established using Ni-NTA cartridges also provided by IBA GmbH (data not shown). This 
Ni-NTA purification protocol (II.2.2.4.2) was used as an alternative for the enrichment of 
bispecific pHEN3CWP+9Strep phages in order to facilitate their detection in immunogold 
assays (Fig.III-26).  
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III.4 Final discussion 
III.4.1 Automation and miniaturization of phage display 
With the human genome project approaching completion (International Human Genom 
Sequencing Consortium; 2004), there is a growing interest in functional analysis of gene 
products. The characterization of large numbers of proteins, their expression pattern and in 
vivo localization demand the use of automated and minituarized technologies that maintain a 
logistic link to the encoding genes. As a complementary approach, phage display is used for 
recombinant protein expression and the selection of specifically interacting molecules. 
Cloning of libraries of genes into phage or phagemid vectors provides a physical link 
between expressed protein and its encoding DNA sequence. Therefore, phage display 
describes a powerful tool for proteomic applications, especially for screening of novel 
therapeutic and diagnostic proteins as well as for epitope mapping or for the identification 
and validation of novel targets. In the emerging field of proteomics, there is an urgent need 
for high-throughput technologies for automated library handling and phage display selection. 
Currently, suitable technologies have been developed by adapting the basic selection steps 
of the panning procedure to robotics (Walter et al. 2001; Konthur and Walter 2002; Hallborn 
and Carlsson 2002; Bradbury 2003b). All panning steps, from selection, washing, elution of 
bound phages, infection spreading, colony-picking, arraying clones into multi-well microtiter 
plates through to screening by phage ELISA can be ran automatically on commercial 
robotics. These high-throughput technologies for automated library handling have been 
shown to combine efficiency with low consumption of the precious library (Hust and Dübel 
2004). 
This scientific trend and the economically requests within the field of proteomics and protein 
drug development describe the need for a novel highly innovative technology, that provides 
an even faster and more efficient automated high-throughput screening system based on 
phage display technology. Therefore, an interdisciplinary project was initiated by the 
Fraunhofer Gesellschaft in order to develop a novel protein microarray platform, called 
Protein Nanochip (Fig.I-9). This new chip-based platform technology should lead to 
miniaturisized devices, which enable the detection and characterization of before unknown 
protein-protein-interactions on a single molecule level. The concept of the Protein Nanochip 
circumvents the entire panning procedure because single binding partners can be directly 
selected by a novel laser-based detection system, FACS separation and subsequent 
analysis by duplex-PCR. This would make the multiple rounds of incubation, washing, elution 
and amplification of the recombinant phages superfluous and dramatically accelerate the 
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screening process. An additional advantage of the Protein Nanochip is the possibility for 
screening two phage libraries against each other and therefore allowing the identification of 
new targets and their specific ligands within one single screening step. For the realization of 
such a device a nano-structured chip surface was to be developed by one of the partners 
allowing the immobilization of phage libraries by side-directed binding of single phages on a 
10nm activated dot within a well-defined pattern on the chip surface. This “organized” 
immobilization pattern of the single members of a first phage library on the chip allows the 
exact localization of each specific binding pair after incubation with a second library using the 
specific labelling of these secondary phage particles. The second library has to be applied in 
solution to the immobilized one and specific binding partners are detected after a suitable 
washing procedure. To obtain exact localization a sensitive laser detection system was to be 
developed because the determination of the exact position is essential for a selective 
delamination of single binding partners. Specific delamination was to be achieved by using 
photosensitive linkers for immobilization of the phage library, which than might be selectively 
cut by an appropriate laser impulse. Finally, released binding partners should be separated 
by flow cytrometry and analyzed by duplex-PCR using the genetic information incorporated 
within the two phage particles. The biological content mainly the generation of bispecific 
filamentous bacteriophages, suitable for the envisaged application, described the focus of 
this doctoral thesis. The establishment of a novel vector system for the generation of 
bispecific filamentous bacteriophages allowing the side-directed immobilization of protein 
libraries onto the surface of the Protein Nanochip was successfully done. 
The data generated within this thesis showed that the Strep-tag®/Strep-Tactin® technology in 
combination with bispecific filamentous bacteriophages makes the generation of the Protein 
Nanochip possible and thus allows the automated screening of two different protein libraries 
against each others in a high-throughput manner. The main obstacle of this project was the 
generation of bispecific filamentous bacteriophages and two different approaches were 
successfully developed within this thesis. 
The first approach describes the usage of a pVI/pIX phage vector system, that seems to 
allow the generation of bispecific phages simultaneously displaying library proteins as a 
fusion to pVI proven by the functional CD30R-display and a peptide fused to pIX as proven 
by the successful insertion of a G4S-linker and a XhoI/NheI-restriction site downstream of the 
second triplet of geneIX. However, the decreased assembly efficiency of CD30R-displaying 
phages indicates that the size of the libraries created with a pVI/IX phage vector will be 
limited to a maximum diversity of 107. The second approach describes the usage of a 
bispecific phagemid vector system and the production of functional bispecific filamentous 
bacteriophages simultaneously displaying a scFv antibody fused to pIII and the Strep-tag® 
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fused to pIX, which was confirmed by Phage ELISA and immunogold assay. However, a 
purification procedure was necessary for the detection of these bispecific phages. Both 
strategies lead to the production of bispecific filamentous bacteriophages that allows the 
side-directed immobilization of protein libraries onto the surface of the envisaged Protein 
Nanochip and thus provide the main tool for the generation of this highly innovative protein 
microarray device. 
Considering the assembly problem of the bispecific phage vector system and the need for a 
purification procedure for the bispecific phagemid vector system, an additional strategy was 
developed describing an alternative way for the generation of bispecific phages combining 
pIII- and pIX-display. The functional display of peptides of at least nine amino acids on pIX 
coat protein using a genetically modified phage vector (fd-g9m, Fig.III-9) leads to the idea to 
create a bispecific phage vector based on fd-tet-DOG1 (Clackson et al. 1991). Phage vector 
fd-tet-DOG1 possesses the capability for multivalent display of foreign proteins on pIII coat 
protein and by insertion of a DNA sequence directly downstream of the second triplet of 
geneIX it should be possible to produce bispecific filamentous bacteriophages. These 
bispecific phages would multivalently display the library proteins on pIII coat protein and any 
interesting peptide motif on the opposite site fused to all pIX coat protein. Using this kind of 
phage vector no enrichment would be necessary, because all rescued phages would display 
the foreign proteins on their surface due to the multivalent display. In addition, there is no 
limitation in the size of the created protein libraries as shown with the pVI-system because 
the library proteins are displayed on pIII coat protein. However, as mentioned above these 
phages will show a decreased infectivity. This would not be a problem for the Protein 
Nanochip, which circumvents the entire panning procedure but perhaps for alternative 
interesting applications. Therefore an additional strategy was thought to provide the best 
solution for the generation of bispecific filamentous bacteriophages allowing the automation 
of the phage display screening procedure. 
The generation of a novel helperphage in combination with standard pIII phagemid vectors 
could provide the best solution. The insertion of a DNA sequence directly downstream of the 
second triplet of geneIX within the helperphage genome encoding for small peptides not 
longer than nine amino acids (e.g. the Strep-tag®) should allow the generation of bispecific 
filamentous bacteriophages. This system would lead to phages monovalently displaying the 
library protein on pIII, encoded by the phagemid vector and simultaneously displaying an 
appropriated peptide motif on all five pIX coat proteins encoded by the helperphage genome. 
The pIX-modified helperphage would be compatible with all pIII phagemid vectors and thus 
allows the automated screening even of already existing protein libraries without sub-cloning 
the libraries into another vector system. All rescued phages would multivalently display the 
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foreign peptide e.g. the Strep-tag® on pIX coat protein and no purification procedure would 
be necessary. In addition, all phages would be infectious due the monovalent library display 
on pIII coat protein. Next to the automation of the screening procedure using a pIX-modified 
helperphage it should be possible to accelerate the rescue of the bispecific phage particles. 
The construction of a helperphage encoding for Strep-tag®/pIX fusion proteins would allow 
purifying the phages by using Strep-Tactin® columns as described and thus circumvents the 
standard rescue procedure, which is a PEG precipitation. In conclusion, these pIX-modified 
helperphages describe an interesting tool for fast rescue of all pIII phagemid libraries and 
would allow the automated screening of these phage libraries if a suitable device like the 
Protein Nanochip will be offered in addition. There will be a great market for this pIX-modified 
helperphage system if an interesting product portfolio is established for this system. A phage 
library purification kit could be based on the usage of Strep-Tactin® columns and a Strep-tag® 
helperphage. In addition, the same helperphage could be offered in combination with an 
automated screening device like the Protein Nanochip allowing the screening of the 
corresponding phage libraries in a high-throughput manner using the bispecific 
characteristics of the final phages.  
However the bispecific filamentous bacteriophages will be produced at the end, they 
describe the main tool necessary for the generation of any kind of screening device allowing 
the automation of the phage display technology. Finally, these bispecific filamentous 
bacteriophages in combination with the Strep-tag®/Strep-Tactin® technology makes the 
generation of the Protein Nanochip possible and thus allows the automated screening of 
protein libraries. Even if the Protein Nanochip itself will never be achieved, bispecific 
filamentous bacteriophages will be used for the establishment of other automated screening 
systems allowing the screening of two different protein libraries against each other. A fluidic 
screening system for example could be envisaged using two differently labelled phage 
libraries. The integration of fluorescent dyes should be possible by using bispecific phages 
displaying a Strep-tag® in addition to the protein library and label them by applying 
fluorescent Strep-Tactin® conjugates to the rescued phages. Alternatively a genetical 
integration of fluorescent proteins is feasible. Finally, it should be possible to distinguish 
between single phages and specific binding phage pairs by a read-out of double signals or 
usage of fluorescence resonance energy transfer (FRET). Specific binding phages should be 
separable by FACS and might be analyzed by duplex-PCR according to the principle 
described for the Protein Nanochip.  
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III.4.2 Alternative applications of bispecific bacteriophages 
In addition to the automation of the phage display technology and the establishment of novel 
high-throughput screening systems, it is also envisaged to use bispecific filamentous 
bacteriophages for therapeutic applications. Chen et al. published an interesting therapeutic 
application within the field of cancer treatment (Chen et al. 2004). The described principle to 
specifically target therapeutic proteins within the human body by using bispecific phages as a 
vehicle will definitely be expanded in the future. In addition to several other interesting drug 
delivery applications it should be possible to use the same principle for example for novel 
vaccination strategies. Bispecific phages may direct vaccines displayed on their surface to 
antigen presenting cells and induce the appropriate immune response. This would advance 
the methology described by Bastien, who already showed specific immune responses 
caused by filamentous bacteriophages (Bastien et al. 1997). Another interesting application 
was published by Carrera (Carrera et al. 2004). He used filamentous bacteriophages as a 
vector-mediated delivery system to the brain (Frenkel and Solomon 2002) and developed a 
novel approach for treating cocaine addiction. An adjustment of bispecific filamentous 
bacteriophages to this application would provide a more specific delivery system and might 
reduce side effects. According to these applications, several other therapeutic or diagnostic 
approaches as well as vaccination strategies might be feasible using bispecific filamentous 
bacteriophages. 
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IV Summary 
Phage display is a powerful tool for screening large protein libraries in order to identify novel 
therapeutics, diagnostics or vaccines. In the emerging field of protein based drug 
development, there is an urgent need for high-throughput technologies for automated library 
handling and phage display selection. Currently, suitable technologies have been developed 
by adapting the basic selection steps of the phage display panning procedure to robotics. 
This thesis presents an innovative strategy for the generation of an even faster high-
throughput screening system, called Protein Nanochip. The basis for this novel protein 
microarray device was established within this thesis circumventing the entire panning 
procedure through direct laser-based detection of singular binding partners, combined with 
FACS, and final identification of the interacting partners by duplex-PCR and sequencing. 
This technology is suitable for screening of an immobilized phage library against a second 
fluorescent labelled phage library and therefore allows the identification of new targets and 
their specific ligands within one single automated screening step. For the development of this 
highly innovative screening devise a bispecific filamentous bacteriophage and a suitable 
technology for side-directed immobilization of these phages onto the surface of the Protein 
Nanochip had to be developed.  
Two different strategies were investigated for the generation of bispecific filamentous 
bacteriophages. First of all, a modified phage vector based on the well-characterized fd-tet 
vector was established. The final bispecific phage vector was generated by insertion of a 
cloning site and an appropriate linker upstream of geneVI and another cloning site and an 
appropriate linker downstream of the second triplet of geneIX. Multivalent display of the 
extracellular domain of the human CD30 receptor fused to the C-terminus of the pVI coat 
protein was shown to be feasible but reduced the assembly efficiency and therefore would 
decrease the diversity of corresponding protein libraries. Multivalent display of single chain 
Fv antibodies fused to pIX coat protein showed a lethal effect on the bacterial host, whereas 
multivalent display of small peptides on the same coat protein was shown to be feasible and 
provides a tool for the generation of recombinant phages not inhibiting the propagation of the 
bacterial host. These results indicate that there might be an option for the generation of 
bispecific filamentous bacteriophages using a pVI/pIX-phage vector system. The final phage 
particles would multivalently display peptides as a fusion to pIX coat protein, which could be 
used for the side-directed immobilization and simultaneously display library proteins as a 
fusion to all five pVI coat proteins. However, there will be a limitation in the diversity of the 
corresponding library displayed on pVI coat protein.  
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Therefore, a novel phagemid vector system for the generation of bispecific filamentous 
bacteriophages was developed. The final phagemid vector was generated by insertion of a 
second expression cassette encoding geneIX into the well-established pHENHi phagemid 
vector. This bispecific phagemid vector was designed for library display on pIII coat protein 
and simultaneous display of functional peptides or proteins for side-directed immobilization or 
labelling on pIX coat protein. Finally, a single chain Fv antibody encoding DNA sequence 
was fused to geneIII and the Strep-tag® encoding DNA to geneIX. Functional coexpression of 
the resulting scFvCWP/pIII- and Strep-tag®/pIX-fusion proteins as well as their incorporation 
into correctly assembled phage particles was verified by phage ELISA and immunogold 
assay with subsequent electron microscopy. These results provided evidence for functional 
display of both the single chain Fv antibody on pIII coat protein and the Strep-tag® on pIX 
coat protein and prove the concept of the novel phagemid vector system as a suitable tool for 
the generation of bispecific filamentous bacteriophages displaying two different foreign 
proteins on their opposite sides. 
The Strep-tag® technology was shown to provide a universal tool for purification, detection 
and side-directed immobilization of Strep-tag®-displaying filamentous bacteriophages. These 
phages could be enriched 16-fold using Strep-Tactin® cartridges and thus allowed the 
enrichment of bispecific phages that represented less than 1% of the initially rescued phage 
population, using the bispecific phagemid vector system. In addition, side-directed 
immobilization of Strep-tag®-displaying phages was shown by phage ELISA either directly on 
Strep-Tactin® coated surfaces or indirectly on biotinylated surfaces via soluble Strep-Tactin®. 
In conclusion, a novel phagemid system for the generation of bispecific filamentous 
bacteriophages, and suitable technologies for purification, detection and side-directed 
immobilization of these phages were successfully developed allowing the immobilization of 
any kind of phage libraries on the biotinylated surface of the Protein Nanochip or comparable 
devices. In addition, labelling of protein libraries with a fluorescent dye can be realized using 
this novel phagemid vector system. Fluorescent proteins might be recombinantly 
incorporated within the phage particles by fusing the corresponding DNA to geneIX or by 
applying fluorescent Strep-Tactin® conjugates to Strep-tag®-displaying phages. Therefore, 
the bispecific phagemid vector system in combination with the adapted Strep-tag® technology 
represents an initial step toward the establishment of the Protein Nanochip allowing the 
automated screening of two different protein libraries against each other.  
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V Appendix 
V.1 List of abbreviations 
(+)    viral (coding) strand of DNA 
(-)    complementary strand of viral DNA 
°C    degree Celsius 
%    percentage 
A    adenine 
aa    amino acid(s) 
Ab    antibody 
ABTS    2,2’-azino-di-[3-ethylbenzthiazoline sulfonate(6)] 
Amp    ampicillin 
Asn    asparagines 
AP    alkaline phosphatase 
bp    base pair 
BSA    bovine serum albumin 
C    cytosine 
cDNA    complementary DNA 
cfu    colony-forming unit(s) 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleotide triphosphate 
dsDNA   double-stranded DNA 
E. coli    Escherichia coli 
ELISA    enzyme-linked immunosorbent assay 
Fc    fragment crystalline 
G    guanine 
GAM    goat anti-mouse antibody 
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GAR    goat anti-rabbit antibody 
Gln    glutamine 
Glu    glutamic acid 
h    hours(s) 
His    histidine 
HRP    horseradish peroxidase 
Ig    immunoglobulin 
IgG    immunoglobulin G 
Kan    kanamycin 
Kb    kilobase 
KDa    kilo Dalton 
l    liter(s) 
LB    Luria broth 
Lys    lysine 
M    molarity (mol/l) 
mAb    monoclonal antibody 
MCS    multiple cloning site 
min    minute(s) 
mol    molar 
mmol    millimolar 
mRNA    messenger RNA 
MW    molecular weight 
µl    mikroliter 
µm    mikrometer 
nm    nanometer 
OD    optical density 
PBS    phosphate buffered saline 
PBS-T    phosphate buffered saline containing 0.05% (v/v) Tween 20 
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PCR    polymerase chain reaction 
PEG    polyethylene glycol 
Phe    phenylalanine 
Pro    proline 
rAb    recombinant antibody 
RNA    ribonucleic acid 
rpm    rotations per minute 
RT    room temperature 
scFv    “single chain Fragment variable” 
Ser    serine 
SOE    splicing by overlap extension 
ssDNA    single-stranded DNA 
T    thymine 
Taq    Thermus aquaticus 
Tet    tetracycline 
Tris    trishydroxymethylaminomethane 
Trp    tryptophan 
U    unit(s) 
UV    ultraviolet 
V    Volt 
VH    variable region of heavy chain 
VL     variable region of light chain 
v/v    volume pre volume 
v/w    volume per weigth 
w/v    weigth per volume 
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V.2 Vectors 
V.2.1 Phage vectors 
 
 
phage vector geneIX modification geneX insert geneVI modification geneVI insert 
fd-tet no no no no 
fd-g6m no no G3SG2 and SfiI/NotI no 
fd-g6/9m XhoI/NheI and G4S  no G3SG2 and SfiI/NotI no 
fd-g6CD30/9m XhoI/NheI and G4S no G3SG2 and SfiI/NotI CD30R cDNA 
fd-g9m XhoI/NheI and G4S no no no 
fd-g9Ki4 XhoI/NheI and G4S Ki-4(scFv) DNA no no 
 
 
gene VIIIgene VII gene IX 
fd-tet 
gene III gene I/XI gene VI
SfiI/NotI 
gene VIIIgene VII gene IX 
fd-g6m 
gene III gene I/XI gene VI G3SG2
SfiI/NotI 
gene VIIIgene VII gene IX 
fd-g6/9m 
gene III gene I/XI gene VI G3SG2G4S 
XhoI/NheI 
gene VII gene IX G4S 
XhoI/NheI NotI 
fd-g6CD30/9m 
CD30R gene I/XI gene VI G3SG
SfiI 
gene VIIIgene VII gene IX
fd-g9m 
gene III gene I/XI gene VIG4S 
XhoI/NheI 
gene VII gene IX 
fd-g9Ki4 
Ki-4(scFv) gene I/XI gene VI G4S 
XhoI NheI 
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V.2.2 Phagemid vectors 
 
pHEN3+9 
pHEN4II myc gene III lac pelB 
SfiI/BstEII AscI/NotI 
L218 
pHENHi myc 6xHi gene III lac pelB 
SfiI/BstEII AscI/NotI 
L218 
pHEN-Strep myc 6xHi gene III lac pelB Strep 
pHEN9 myc gene IX lac pelB L218 
SfiI/BstEII AscI/NotI 
pHEN9-Strep myc gene IX lac pelB Strep 
pHEN9-CWP myc gene IX lac pelB scFvCWP 
lac pelB scFvCWP myc 6xHi gene III pHEN-CWP 
myc gene IX lac pelB MC
XhoI/XbaI/EcoRV/PstI/NcoI 
pHEN9-Bi 
myc his gene III Lac pelB Lac pelB gene IX MCS myc 
pHEN3CWP+9 
scFvCWPD2 
SfiI/BstEII AscI/NotI 
myc his gene III pelB Lac Lac pelB gene IX MCS myc L218 
XhoI/XbaI/EcoRV/PstI/NcoI 
pHEN3CWP+9Strep 
myc his gene III Lac pelB Lac pelB gene IX Strep myc scFvCWPD2 
myc his gene III pelB Lac Lac pelB gene IX Strep myc L218 
pHEN3+9Strep 
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phagemid vector geneIII cassette geneIII insert geneIX cassette geneIX insert 
pHEN4II present no no no 
pHENHi present + 6xHis tag no no no 
pHEN-Strep present  Strep-tag® no no 
pHEN-CWP present scFvCWP  no no 
pHEN9 no no present no 
pHEN9-Strep no no present Strep-tag® 
pHEN9-CWP no no present scFvCWP 
pHEN9-Bi no no present + new MCS no 
pHEN3+9 present + 6xHis tag no present + new MCS no 
pHEN3CWP+9 present + 6xHis tag scFvCWP present + new MCS no 
pHEN3+9Strep present + 6xHis tag no present + new MCS Strep-tag® 
pHEN3CWP+9Strep present + 6xHis tag scFvCWP present + new MCS Strep-tag® 
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